US20080075763A1 - Polycationic sterol derivatives as transfection agents - Google Patents
Polycationic sterol derivatives as transfection agents Download PDFInfo
- Publication number
- US20080075763A1 US20080075763A1 US11/868,184 US86818407A US2008075763A1 US 20080075763 A1 US20080075763 A1 US 20080075763A1 US 86818407 A US86818407 A US 86818407A US 2008075763 A1 US2008075763 A1 US 2008075763A1
- Authority
- US
- United States
- Prior art keywords
- group
- compound
- head group
- cholesterol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001890 transfection Methods 0.000 title description 7
- 229930182558 Sterol Natural products 0.000 title 1
- 150000003432 sterols Chemical class 0.000 title 1
- 235000003702 sterols Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 104
- 238000000034 method Methods 0.000 claims abstract description 78
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 74
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims abstract description 58
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 125000003277 amino group Chemical group 0.000 claims abstract description 15
- 208000026350 Inborn Genetic disease Diseases 0.000 claims abstract description 14
- 208000016361 genetic disease Diseases 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims abstract 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 98
- 239000002502 liposome Substances 0.000 claims description 79
- 229920000768 polyamine Polymers 0.000 claims description 64
- 125000002091 cationic group Chemical group 0.000 claims description 58
- -1 cationic lipid Chemical class 0.000 claims description 35
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 28
- 235000012000 cholesterol Nutrition 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 229940063673 spermidine Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
- QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 238000001476 gene delivery Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 238000012546 transfer Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 11
- 150000001540 azides Chemical class 0.000 description 10
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 238000005447 aza-Wittig reaction Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000012267 brine Substances 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 150000001414 amino alcohols Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000002808 molecular sieve Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 6
- 235000009518 sodium iodide Nutrition 0.000 description 6
- 229940063675 spermine Drugs 0.000 description 6
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical class C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 5
- 238000007126 N-alkylation reaction Methods 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 5
- UPCIBFUJJLCOQG-UHFFFAOYSA-L ethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethyl-methylamino]ethyl]-dimethylazanium;dibromide Chemical compound [Br-].[Br-].CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC UPCIBFUJJLCOQG-UHFFFAOYSA-L 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000007327 hydrogenolysis reaction Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- WJJIRYDUUXGIKR-UHFFFAOYSA-N CC(=O)NCCCNCCCCNCCCNCCN Chemical compound CC(=O)NCCCNCCCCNCCCNCCN WJJIRYDUUXGIKR-UHFFFAOYSA-N 0.000 description 4
- KWTKCDKVFYLEEX-UHFFFAOYSA-N CC(=O)NCCCNCCCCNCCCNCCN.CC(=O)NCCCNCCCCNCCN.CC(=O)NCCCNCCCNCCN.CC(=O)NCCCNCCN.CC(=O)NCCNCCCCN.CC(=O)NCCNCCCCNCCCN.CC(=O)NCCNCCCN.CC(=O)NCCNCCCNCCN.CC(=O)NCCNCCN.CC(=O)NCCNCCNCCCN Chemical compound CC(=O)NCCCNCCCCNCCCNCCN.CC(=O)NCCCNCCCCNCCN.CC(=O)NCCCNCCCNCCN.CC(=O)NCCCNCCN.CC(=O)NCCNCCCCN.CC(=O)NCCNCCCCNCCCN.CC(=O)NCCNCCCN.CC(=O)NCCNCCCNCCN.CC(=O)NCCNCCN.CC(=O)NCCNCCNCCCN KWTKCDKVFYLEEX-UHFFFAOYSA-N 0.000 description 4
- XQEHVCZYWIUNIH-UHFFFAOYSA-N CC(=O)NCCCNCCCCNCCCNCCN.CC(=O)NCCCNCCCCNCCN.CC(=O)NCCCNCCCNCCN.CC(=O)NCCCNCCN.CC(=O)NCCNCCCCN.CC(=O)NCCNCCCCNCCCN.CC(=O)NCCNCCCN.CC(=O)NCCNCCCNCCN.CC(=O)NCCNCCNCCCN Chemical compound CC(=O)NCCCNCCCCNCCCNCCN.CC(=O)NCCCNCCCCNCCN.CC(=O)NCCCNCCCNCCN.CC(=O)NCCCNCCN.CC(=O)NCCNCCCCN.CC(=O)NCCNCCCCNCCCN.CC(=O)NCCNCCCN.CC(=O)NCCNCCCNCCN.CC(=O)NCCNCCNCCCN XQEHVCZYWIUNIH-UHFFFAOYSA-N 0.000 description 4
- JYPFFHLEKZEMSD-UHFFFAOYSA-N CC(=O)NCCCNCCCCNCCCNCCN.CC(=O)NCCCNCCCCNCCN.CC(=O)NCCCNCCCNCCN.CC(=O)NCCCNCCN.CC(=O)NCCNCCCCN.CC(=O)NCCNCCCN.CC(=O)NCCNCCCNCCN.CC(=O)NCCNCCN.CC(=O)NCCNCCNCCCN Chemical compound CC(=O)NCCCNCCCCNCCCNCCN.CC(=O)NCCCNCCCCNCCN.CC(=O)NCCCNCCCNCCN.CC(=O)NCCCNCCN.CC(=O)NCCNCCCCN.CC(=O)NCCNCCCN.CC(=O)NCCNCCCNCCN.CC(=O)NCCNCCN.CC(=O)NCCNCCNCCCN JYPFFHLEKZEMSD-UHFFFAOYSA-N 0.000 description 4
- RXHXSUDUYJXLKE-UHFFFAOYSA-N CC(=O)NCCNCCCN Chemical compound CC(=O)NCCNCCCN RXHXSUDUYJXLKE-UHFFFAOYSA-N 0.000 description 4
- GWUQMRBTPVKMJX-UHFFFAOYSA-N CC(=O)NCCNCCCNCCN Chemical compound CC(=O)NCCNCCCNCCN GWUQMRBTPVKMJX-UHFFFAOYSA-N 0.000 description 4
- AYQBNMYQPOEJOR-LQQJEMICSA-N [H][C@@]12CC=C3C[C@@H](C(C)C)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1([H])[C@H](C)CCCC(C)C Chemical compound [H][C@@]12CC=C3C[C@@H](C(C)C)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1([H])[C@H](C)CCCC(C)C AYQBNMYQPOEJOR-LQQJEMICSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000005976 benzyloxycarbonylation reaction Methods 0.000 description 4
- BELZJFWUNQWBES-UHFFFAOYSA-N caldopentamine Chemical compound NCCCNCCCNCCCNCCCN BELZJFWUNQWBES-UHFFFAOYSA-N 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000003328 mesylation reaction Methods 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001649 bromium compounds Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- KLHSDMQFUVANEB-MELZOAELSA-L hexadecyl-[(2r,3r)-4-[hexadecyl(dimethyl)azaniumyl]-2,3-dimethoxybutyl]-dimethylazanium;dibromide Chemical compound [Br-].[Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C[C@@H](OC)[C@H](OC)C[N+](C)(C)CCCCCCCCCCCCCCCC KLHSDMQFUVANEB-MELZOAELSA-L 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 3
- OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 description 2
- 0 *C(NCCNCCCN)=O Chemical compound *C(NCCNCCCN)=O 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical class NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000004819 silanols Chemical class 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical group [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ZAXCZCOUDLENMH-UHFFFAOYSA-N 3,3,3-tetramine Chemical compound NCCCNCCCNCCCN ZAXCZCOUDLENMH-UHFFFAOYSA-N 0.000 description 1
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 102100022653 Histone H1.5 Human genes 0.000 description 1
- 101000899879 Homo sapiens Histone H1.5 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- VIGMAPZYSWAUDT-UHFFFAOYSA-N N[SiH2]O Chemical class N[SiH2]O VIGMAPZYSWAUDT-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- BDLVNNJRAIUIMO-UHFFFAOYSA-N amino(hydroxy)silicon Chemical compound N[Si]O BDLVNNJRAIUIMO-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OTBHHUPVCYLGQO-UHFFFAOYSA-N bis(3-aminopropyl)amine Chemical compound NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical class C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Definitions
- the present invention relates to a compound.
- the present invention relates to processes for making the compound and to the use of that compound in therapy, in particular gene therapy (especially gene transfer).
- One aspect of gene therapy involves the introduction of foreign nucleic acid (such as DNA) into cells, so that its expressed protein may carry out a desired therapeutic function.
- foreign nucleic acid such as DNA
- Examples of this type of therapy include the insertion of TK, TSG or ILG genes to treat cancer; the insertion of the CFTR gene to treat cystic fibrosis; the insertion of NGF, TH or LDL genes to treat neurodegenerative and cardiovascular disorders; the insertion of the IL-1 antagonist gene to treat rheumatoid arthritis; the insertion of HIV antigens and the TK gene to treat AIDS and CMV infections; the insertion of antigens and cytokines to act as vaccines; and the insertion of ⁇ -globin to treat haemoglobinopathic conditions, such as thalassaemias.
- cationic liposomes which usually consist of a neutral phospholipid and a cationic lipid—have been used to transfer DNA 4 , mRNA 5 , antisense oligonucleotides 6 , proteins 7 and drugs 8 into cells.
- a number of cationic liposomes are commercially availabe 4,9 and many new cationic lipids have recently been synthesised 10 . The efficacy of these liposomes has be en illustrated by both in vitro 4 and in vivo 11 .
- a neutral phospholipid useful in the preparation of a cationic liposome is N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride, otherwise known as “DOTMA”.
- DOTMA N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride, otherwise known as “DOTMA”.
- the structure of DOTMA is shown in FIG. 1 .
- DOPE neutral phospholipid dioleoylphosphatidylethanolamine
- DC-Chol cationic lipid, 3 ⁇ -[(N,N-dimethylaminoethyl)carbamoyl]cholesterol
- a lipid has been synthesised by reacting spermidine and cholesterol chloroformate in CH 2 Cl 2 in the presence of N,N-diisoprophylethylamine 18 .
- a compound capable of acting as a cationic lipid comprising a cholesterol group having linked thereto a head group; and wherein the head group is more positive than the head group of DC-Chol; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH 2 Cl 2 in the presence of N,N-diisoprophylethylamine.
- the head group of DC-Chol is Me 2 N(CH 2 ) 2 NH—.
- a process of preparing a compound according to the present invention comprising reacting a cholesterol group with a head group.
- a cationic liposome formed from the compound according to the present invention or a compound when prepared by the process of the present invention.
- a method of preparing a cationic liposome comprising forming the cationic liposome from the compound according to the present invention or a compound when prepared by the process of the present invention.
- a cationic liposome according to the present invention or a cationic liposome as prepared by the method of the present invention for use in therapy is provided.
- a cationic liposome according to the present invention or a cationic liposome as prepared by the method of the present invention in the manufacture of a medicament for the treatment of genetic disorder or condition or disease.
- a pharmaceutical composition comprising a compound according to the present invention or a compound when prepared by the process of the present invention admixed with a pharmaceutical and, optionally, admixed with a pharmaceutically acceptable diluent, carrier or excipient.
- a pharmaceutical composition comprising a cationic liposome according to the present invention or a cationic liposome as prepared by the method of the present invention admixed with a pharmaceutical and, optionally, admixed with a pharmaceutically acceptable diluent, carrier or excipient.
- a key advantage of the compound of the present invention is that it can be used as a cationic lipid (amphiphile) in the preparation of a cationic liposome useful in gene therapy, in particular the transfer of nucleic acids (including genes and antisense DNA/RNA) into cells (in vitro and in vivo) to derive a therapeutic benefit.
- the cholesterol group can be cholesterol or a derivative thereof.
- cholesterol derivatives include substituted derivatives wherein one or more of the cyclic CH 2 or CH groups and/or one or more of the straight-chain CH 2 or CH groups is/are appropriately substituted. Alternatively, or in addition, one or more of the cyclic groups and/or one or more of the straight-chain groups may be unsaturated.
- the cholesterol group is cholesterol. It is believed that cholesterol is advantageous as it stabilises the resultant liposomal bilayer.
- the cholesterol group is linked to the head group via a carbamoyl linkage. It is believed that this linkage is advantageous as the resultant liposome has a low or minimal cytotoxicity.
- the head group is a polyamine group. It is believed that the polyamine group is advantageous because it increases the DNA binding ability and efficiency of gene transfer of the resultant liposome.
- the polyamine group is a naturally occurring polyamine. It is believed that the polyamine head-group is advantageous because the increased amino functionality increases the overall positive charge of the liposome.
- polyamines are known to both strongly bind and stabilise DNA 14 . In addition, polyamines occur naturally in cells and so it is believed that toxicological problems are minimised 15 .
- Suitable polyamines include spermidine, spermine, caldopentamine, norspermidine and norspermine. These polyamines are shown in FIG. 4 .
- the polyamine is spermidine or spermine as these polyamines are known to interact with single or double stranded DNA.
- An alternative preferred polyamine is caldopentamine.
- a preferred compound is spermidine linked to cholesterol via a carbamate linkage.
- This compound is shown in FIG. 5 . It is believed that the polyamino head group is advantageous for DNA condensation, the carbamate linkage is stable but biodegradable and the cholesteryl group imparts bilayer rigidity.
- the carbamate linkage may be part of, or an integral component of, the head group.
- Another preferred compound is spermine linked to cholesterol via a carbamate linkage.
- the polyamino head group is advantageous for DNA condensation, the carbamate linkage is stable but biodegradable and the cholesteryl group imparts bilayer rigidity.
- the compound is in admixture with or associated with a nucleotide sequence.
- the nucleotide sequence may be part or all of an expression system that may be useful in therapy, such as gene therapy.
- the process comprises at least one step utilising aza-Wittig methodology.
- the process comprises the use of trimethylphosphine.
- the process comprises the use of a molecular sieve.
- the cationic liposome is formed from the compound of the present invention and a neutral phospholipid—such as DOTMA or DOPE.
- a neutral phospholipid such as DOTMA or DOPE.
- the neutral phospholipid is DOPE.
- two or more of the amine groups of the polyamine group of the present invention are separated by one or more groups which are not found in nature that separate amine groups of naturally occurring polyamine compounds (i.e. preferably the polyamine group of the present invention has unnatural spacing).
- the present invention provides a compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; and wherein the head group is more positive than the head group of DC-Chol; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH 2 Cl 2 in the presence of N,N-diisoprophylethylamine.
- a preferred embodiment of the present invention is a compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; wherein the cholesterol group is cholesterol; and wherein the head group is a polyamine group; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH 2 Cl 2 in the presence of N,N-diisoprophyl-ethylamine.
- a more preferred embodiment of the present invention is a compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; wherein the cholesterol group is cholesterol; wherein the head group is a polyamine group; and wherein the cholesterol group is linked to the head group via a carbamoyl linkage; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH 2 Cl 2 in the presence of N,N-diisoprophylethylamine.
- a highly preferred embodiment of the present invention is a compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; wherein the cholesterol group is cholesterol; wherein the head group is a polyamine group; wherein the cholesterol group is linked to the head group via a carbamoyl linkage; and wherein the polyamine group is a naturally occurring polyamine, such as any one of spermidine, spermine or caldopentamine; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH 2 Cl 2 in the presence of N,N-diisoprophylethylamine.
- FIG. 1 which is a structure
- FIG. 2 which is a structure
- FIG. 3 which is a structure
- FIG. 4 which is a series of structures
- FIG. 5 which is a structure
- FIG. 6 which is a structure
- FIG. 7 which includes a reaction scheme
- FIG. 8 which includes a reaction scheme and a Table of results
- FIG. 9 which includes a reaction scheme and a Table of results
- FIG. 10 which includes a reaction scheme and a Table of results
- FIG. 11 which includes a reaction scheme
- FIG. 12 which includes a reaction scheme and a Table of results
- FIG. 13 which includes a reaction scheme and a Table of results
- FIG. 14 which includes a reaction scheme and a Table of results
- FIG. 15 which includes a reaction scheme and a Table of results
- FIG. 16 which includes a reaction scheme and a Table of results
- FIG. 17 which includes a reaction scheme
- FIG. 18 which includes a reaction scheme and a series of results
- FIG. 19 which includes a reaction scheme and a series of results
- FIG. 20 which includes a reaction scheme and a Table of results
- FIG. 21 which includes a reaction scheme and a Table of results
- FIG. 22 which presents a model
- FIG. 23 which presents data from some studies
- FIG. 24 which presents data from some studies
- FIG. 25 which presents data from some studies
- FIG. 26 which presents a reaction scheme
- FIG. 27 which presents a reaction scheme
- FIG. 28 which presents a reaction scheme
- FIG. 29 which presents some formulae.
- DC-Chol was used as a template for the synthesis of more efficient gene transfer lipids, due to its good gene transfer ability 12 and low cytotoxicity 13 .
- the head group of DC-Chol was changed to a series of polyamine head-groups.
- the desired aldehyde could also be synthesised from aminoalcohols (see FIG. 9 , referenced as 5) in excellent yield, this time by N-protection with cholesteryl chloroformate to give alcohols (see FIG. 9 , referenced as 8), followed by Swern-type oxidation 17 to aldehydes (see FIG. 9 , referenced as 9).
- the aldehydes (9) were isolated as white crystalline solids which, in contrast with analogous aldehydes with different protecting groups, proved to be extremely stable, easy to handle and could be stored for long periods of time without any discernible decomposition.
- Liposomes containing the new lipids could be prepared using the following general procedure which by way of example refers to lipid (2) and DOPE.
- Lipid (2) (6 ⁇ mol) and DOPE (298 ⁇ l of a 10 mg/ml solution in CHCl 3 , 4 ⁇ mol) were added via syringe to freshly distilled CH 2 Cl 2 (5 ml) under a nitrogen atmosphere.
- 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (5 ml of a 20 mM solution adjusted to pH 7.8) was added.
- the two phase mixture was sonicated for 3 minutes and the organic solvents were removed under reduced pressure.
- the resulting liposome suspension was then sonicated for a further 30 min, yielding liposomes with an average diameter of 150 nm (as determined using a Coulter N4 MD photon correlation spectrometer).
- FIGS. 11-21 For these further studies reference can also be made to FIGS. 11-21 .
- the pale yellow solution was then washed with saturated ammonium chloride (150 ml), saturated sodium bicarbonate (80 ml) and water (100 ml).
- the aqueous extracts were combined and washed with CH 2 Cl 2 (100 ml).
- the CH 2 Cl 2 extracts were combined, washed with brine (100 ml) and dried over anhydrous sodium sulfate.
- the solvent was then evaporated in vacuo to give a pale yellow solid.
- the crude aldehyde was then purified by flash column chromatography (ether) to a white solid.
- FIG. 22 is the putative alignment of DC-Chol 1 and DOPE 2 in cationic liposome bilayer.
- FIG. 23 is an example of in vitro optimisation of pCF1- ⁇ Gal plasmid transfection of CFT1 cells in vitro using complexes of pCF1- ⁇ Gal and cationic liposomes formulated from DC-Chol analogue 8f′ and DOPE 2 (1:1) molar ratio.
- CFT1 cells were transfected with an array of different cationic liposome and plasmid ratios in a 96-well plate. The extent of transfection in each well was determined after 2 days by measuring the levels of ⁇ -galactosidase expression. Plasmid DNA concentration is expressed as the concentration of nucleotides assuming an average nucleotide FWt of 330. Cationic liposome concentration is expressed in ter-Ms of the concentration of the constituent DC-Chol analogue 8f′ alone.
- FIG. 24 presents ran order of DC-Chol polyamine analogues transfecting CFT1 cells in vitro with the pCF1- ⁇ Gal plasmid. Gene delivery activity is expressed as a proportion of the activity measured with standard liposomes containing DC-Chol 1 and DOPE 2. The data shown are the averages of four separate experiments, each performed in triplicate.
- the ratios in curved brackets refer to the DC-Chol analogue:DOPE 2 molar ratio used to formulate the liposomes.
- the numbers in square brackets refer to compound serial numbers. Where appropriate DC-Chol analogue name abbreviations are also included (see experimental).
- FIG. 25 presents the rank order of DC-Chol polyamine analogues transfecting the lungs of female BALB/c mice with the pCF1—CAT plasmid. Mice were instilled with a solution of the plasmid (4 mM nucleotide concentration) and the optimal quantity and ratio of cationic liposome, in a total volume of 100 ⁇ l. Gene delivery activity was determined as a function of chloramphenicol acetyl transferase activity in lung homogenates after 2 days.
- N-cholesteryloxycarbonylaminoaldehydes 3′ were prepared by N-protection of aminoalcohols 4′ with cholesteryl chloroformate followed by Swern-type oxidation [28] of protected alcohols 5′ to give the aldehydes 3′ (see Scheme A in FIG. 26 ).
- aminoaldehydes can be quite unstable and prone to polymerisation but the steric stabilisation of the N-cholesteryl moiety resulted in crystalline compounds which could be stored for extended periods of time without any discernible decomposition.
- N-Benzyloxycarbonyl protected aminoazides 6′ were then prepared in three steps from aminoalcohols 4′ using sequential N-benzyloxycarbonylation, mesylation and azidation (Scheme A). Finally, azides 6′ were coupled to aminoaldehydes 3′ using aza-Wittig methodology [29, 30] giving protected DC-Chol triamine analogues 7′ which were stored at this stage. In our hands, aza-wittig coupling reactions were found to be more efficient with trimethylphosphine rather than the customary triphenylphosphine, in line with literature precedent. [29] Also, the elimination of adventitious water with activated molecular sieves proved helpful to obtain consistently high yields.
- DC-Chol pentamine analogues 16′ could be prepared by aza-Wittig coupling of diaminoaldehyde 14′ to di-N-benzyloxycarbonyl protected diaminoazides 11′.
- DC-Chol pentamine analogues 17′ were then prepared by hydrogenolysis of the protecting groups in the usual way (Scheme C).
- Cationic liposomes were formulated by hydrating a dried lipid film, containing DC-Cholanalogue and DOPE 2 in an appropriate molar ratio of either 1:0, 1:1, 1:2 or 2:1 respectively, and vortex mixing. [32] Cationic liposome/plasmid DNA complexes were then prepared by adding appropriately diluted cationic liposome suspensions into equal volumes of aqueous plasmid DNA solutions at 30° C. and allowing the mixture to equilibrate to ambient temperature over 15 min.
- CFT1 cystic fibrosis airway epithelial
- cationic liposome/plasmid DNA complexes were instilled intranasally into the lungs of female BALB/c mice.
- cationic liposome gene delivery was first optimised in vitro so as to establish the best molar ratio of cationic liposome to plasmid DNA (DNA concentration was expressed as nucleotide concentration) as well as the best absolute quantities of both, as illustrated ( FIG. 23 ). This optimised combination was then tested in vivo. The in vitro results are shown ( FIG. 24 ).
- the analogues were 8a′, 8b′, 8e′, 8f′, 13a′ and 17b′, the first four being triamines, the fifth a tetramine and the sixth a pentamine.
- 8f′ these polyamine analogues contain inter-nitrogen methylene group spacings not normally associated with the natural polyamines spermidine 18′ (see for example FIG. 29 ), spermine 19′ (see for example FIG. 29 ) and pentamine 20′ (see for example FIG. 29 ) upon which these structures are based.
- the best DC-Chol analogues were 13c′, 13f′ and especially 17a′. Both 17a′ and 13c′ also contain unnatural methylene group spacings.
- 17a′ works about 100-fold more effectively in mouse lung than DC-Chol 1 and approx 500-fold relative to plasmid DNA alone ( FIG. 25 ). Only one other cytofectin has been reported to function at this level of efficacy in vivo, namely the lipid 67 21′ (see FIG. 29 ), a “T” shaped tetramine analogue of DC-Chol.
- Analogues 8f′ and 13f′ have been reported previously, either without synthetic characterisation details [32] or else as impure mixtures known as SpdC and SpC respectively. [34] In the former case, in vitro and in vivo gene delivery behaviours were found to be comparable with our results reported here. [32] In the latter case, SpC was reported not to work well and to be relatively toxic. [34] Our data with analogue 13f′ do not support these observations.
- Reagents and conditions i, CH 2 Cl 2 (0.2M), CholOC(O)Cl (0.45 eqv), 5 h, 98-99%; ii, (a) CH 2 Cl 2 (0.1M) (COCl) 2 (1.5 eqv), DMSO (3 eqv), ⁇ 78° C., 15 min; (b) 5′, 15 min; (c) i-Pr 2 NEt (3 eqv) to r.t., 93-97%; iii, (a) CH 2 Cl 2 (0.2M), PhCH 2 OC(O)Cl (0.45 eqv), 10 h; (b) CH 2 Cl 2 (0.2M), Et 3 N (3 eqv), CH 3 SO 2 Cl (2.5 eqv), 0° C.
- Reagents and conditions i, (a) CH 2 Cl 2 (0.2M), PhCH 2 OC(O)Cl (0.45 eqv), 10 h; (b) CH 2 Cl 2 (0.2M), Et 3 N (3 eqv), CH 3 SO 2 Cl (2.5 eqv), 0° C.
- Reagents and conditions i, (a) CH 2 Cl 2 (0.2M), Et 3 N (3 eqv), CH 3 SO 2 Cl (2.5 eqv), 0° C. to r.t., 15 min; (b) DMF (0.15 M), NaBr (5 eqv), 80° C., 2h, 68-87%; ii, (a) 15′, DMF (0.1M), 4′ (5 eqv), K 2 CO 3 (2 eqv), NaI (0.3 eqv), 24-72 h; (b) CH 2 Cl 2 (0.2M), Et 3 N (1.5 eqv), TBDPSCl (1.2 eqv), DMAP (0.1 eqv), 0° C.
- Cationic liposome/plasmid DNA complexes were then prepared as follows.
- Cationic liposomes are heterogeneous, lipid vesicles typically formed from either a single cationic amphiphile (sometimes known as a cytofectin) or more commonly from a combination of a cationic amphiphile and a neutral lipid. They mediate gene delivery by interacting electrostatically with negatively charged DNA sequences forming complexes which may enter cells by endocytosis [221] or phagocytosisl [23] and then release DNA for expression in the cell nucleus.
- the present invention seeks to improve the earlier studies. In addition, the present invention seeks to understand some of the underlying chemical principles behind liposome-mediated gene delivery.
- liposomes were prepared from compounds comprising a cholesterol component and a head group component.
- Other modifications of the present invention will be apparent to those skilled in the art.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method for treating genetic disorders or conditions or diseases in patients in need of such treatments. The method includes administering an effective amount of a compound comprising a cholesterol group or derivative thereof having linked thereto a head group. The head group is more positive than the heat group of DC-Chol. The heat group may be a straight chain polymeric group having two or more amine groups separated by an ethylene group.
Description
- The present invention relates to a compound. In addition, the present invention relates to processes for making the compound and to the use of that compound in therapy, in particular gene therapy (especially gene transfer).
- One aspect of gene therapy involves the introduction of foreign nucleic acid (such as DNA) into cells, so that its expressed protein may carry out a desired therapeutic function.1
- Examples of this type of therapy include the insertion of TK, TSG or ILG genes to treat cancer; the insertion of the CFTR gene to treat cystic fibrosis; the insertion of NGF, TH or LDL genes to treat neurodegenerative and cardiovascular disorders; the insertion of the IL-1 antagonist gene to treat rheumatoid arthritis; the insertion of HIV antigens and the TK gene to treat AIDS and CMV infections; the insertion of antigens and cytokines to act as vaccines; and the insertion of β-globin to treat haemoglobinopathic conditions, such as thalassaemias.
- Many current gene therapy studies utilise adenoviral gene vectors—such as Ad3 or Ad5—or other gene vectors. However, serious problems have been associated with their use.2 This has prompted the development of less hazardous, non-viral approaches to gene transfer.3
- A non-viral transfer system of great potential involves the use of cationic liposomes.4 In this regard, cationic liposomes—which usually consist of a neutral phospholipid and a cationic lipid—have been used to transfer DNA4, mRNA5, antisense oligonucleotides6, proteins7 and drugs8 into cells. A number of cationic liposomes are commercially availabe4,9 and many new cationic lipids have recently been synthesised10. The efficacy of these liposomes has be en illustrated by both in vitro4 and in vivo11.
- A neutral phospholipid useful in the preparation of a cationic liposome is N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride, otherwise known as “DOTMA”. The structure of DOTMA is shown in
FIG. 1 . - One of the most commonly used cationic liposome systems consists of a mixture of a neutral phospholipid dioleoylphosphatidylethanolamine (commonly known as “DOPE”) and a cationic lipid, 3β-[(N,N-dimethylaminoethyl)carbamoyl]cholesterol (commonly known as “DC-Chol”)12. The structure of DOPE is shown in
FIG. 2 . The structure of DC-Chol is shown inFIG. 3 . - A lipid has been synthesised by reacting spermidine and cholesterol chloroformate in CH2Cl2 in the presence of N,N-diisoprophylethylamine18. However, this resulted in a mixture of the lipid and the corresponding regio-isomeric lipid, which mixture proved inseparable by chromatography.
- Despite the efficacy of the known cationic liposomes there is still a need to optimise the gene transfer efficiency of cationic liposomes in human gene therapy10.
- According to one aspect of the present invention there is provided a compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; and wherein the head group is more positive than the head group of DC-Chol; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH2Cl2 in the presence of N,N-diisoprophylethylamine.
- As indicated above, the head group of DC-Chol is Me2N(CH2)2NH—.
- According to another aspect of the present invention there is provided a process of preparing a compound according to the present invention comprising reacting a cholesterol group with a head group.
- According to another aspect of the present invention there is provided a compound according to the present invention or a compound when prepared by the process of the present invention for use in therapy.
- According to another aspect of the present invention there is provided the use of a compound according to the present invention or a compound when prepared by the process of the present invention in the manufacture of a medicament for the treatment of a genetic disorder or a condition or a disease.
- According to another aspect of the present invention there is provided a cationic liposome formed from the compound according to the present invention or a compound when prepared by the process of the present invention.
- According to another aspect of the present invention there is provided a method of preparing a cationic liposome comprising forming the cationic liposome from the compound according to the present invention or a compound when prepared by the process of the present invention.
- According to another aspect of the present invention there is provided a cationic liposome according to the present invention or a cationic liposome as prepared by the method of the present invention for use in therapy.
- According to another aspect of the present invention there is provided the use of a cationic liposome according to the present invention or a cationic liposome as prepared by the method of the present invention in the manufacture of a medicament for the treatment of genetic disorder or condition or disease.
- According to another aspect of the present invention there is provided a combination of a nucleotide sequence and any one or more of: a compound according to the present invention, a compound when prepared by the process of the present invention, a liposome of the present invention, or a liposome as prepared by the method of the present invention.
- According to another aspect of the present invention there is provided a combination according to the present invention for use in therapy.
- According to another aspect of the present invention there is provided the use of a combination according to the present invention in the manufacture of a medicament for the treatment of genetic disorder or condition or disease.
- According to another aspect of the present invention there is provided a pharmaceutical composition comprising a compound according to the present invention or a compound when prepared by the process of the present invention admixed with a pharmaceutical and, optionally, admixed with a pharmaceutically acceptable diluent, carrier or excipient.
- According to another aspect of the present invention there is provided a pharmaceutical composition comprising a cationic liposome according to the present invention or a cationic liposome as prepared by the method of the present invention admixed with a pharmaceutical and, optionally, admixed with a pharmaceutically acceptable diluent, carrier or excipient.
- It is believed that a key advantage of the compound of the present invention is that it can be used as a cationic lipid (amphiphile) in the preparation of a cationic liposome useful in gene therapy, in particular the transfer of nucleic acids (including genes and antisense DNA/RNA) into cells (in vitro and in vivo) to derive a therapeutic benefit.
- The cholesterol group can be cholesterol or a derivative thereof. Examples of cholesterol derivatives include substituted derivatives wherein one or more of the cyclic CH2 or CH groups and/or one or more of the straight-chain CH2 or CH groups is/are appropriately substituted. Alternatively, or in addition, one or more of the cyclic groups and/or one or more of the straight-chain groups may be unsaturated.
- In a preferred embodiment the cholesterol group is cholesterol. It is believed that cholesterol is advantageous as it stabilises the resultant liposomal bilayer.
- Preferably the cholesterol group is linked to the head group via a carbamoyl linkage. It is believed that this linkage is advantageous as the resultant liposome has a low or minimal cytotoxicity.
- Preferably the head group is a polyamine group. It is believed that the polyamine group is advantageous because it increases the DNA binding ability and efficiency of gene transfer of the resultant liposome.
- In one embodiment, preferably the polyamine group is a naturally occurring polyamine. It is believed that the polyamine head-group is advantageous because the increased amino functionality increases the overall positive charge of the liposome. In addition, polyamines are known to both strongly bind and stabilise DNA14. In addition, polyamines occur naturally in cells and so it is believed that toxicological problems are minimised15.
- Typical examples of suitable polyamines include spermidine, spermine, caldopentamine, norspermidine and norspermine. These polyamines are shown in
FIG. 4 . - Preferably the polyamine is spermidine or spermine as these polyamines are known to interact with single or double stranded DNA. An alternative preferred polyamine is caldopentamine.
- Thus, a preferred compound is spermidine linked to cholesterol via a carbamate linkage. This compound is shown in
FIG. 5 . It is believed that the polyamino head group is advantageous for DNA condensation, the carbamate linkage is stable but biodegradable and the cholesteryl group imparts bilayer rigidity. The carbamate linkage may be part of, or an integral component of, the head group. - Another preferred compound is spermine linked to cholesterol via a carbamate linkage. Likewise, it is believed that the polyamino head group is advantageous for DNA condensation, the carbamate linkage is stable but biodegradable and the cholesteryl group imparts bilayer rigidity.
- Preferably the compound is in admixture with or associated with a nucleotide sequence.
- The nucleotide sequence may be part or all of an expression system that may be useful in therapy, such as gene therapy.
- Preferably the process comprises at least one step utilising aza-Wittig methodology.
- Preferably the process comprises the use of trimethylphosphine.
- Preferably the process comprises the use of a molecular sieve.
- Preferably, the cationic liposome is formed from the compound of the present invention and a neutral phospholipid—such as DOTMA or DOPE. Preferably, the neutral phospholipid is DOPE.
- In another embodiment, preferably two or more of the amine groups of the polyamine group of the present invention are separated by one or more groups which are not found in nature that separate amine groups of naturally occurring polyamine compounds (i.e. preferably the polyamine group of the present invention has unnatural spacing).
- In summation, the present invention provides a compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; and wherein the head group is more positive than the head group of DC-Chol; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH2Cl2 in the presence of N,N-diisoprophylethylamine.
- A preferred embodiment of the present invention is a compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; wherein the cholesterol group is cholesterol; and wherein the head group is a polyamine group; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH2Cl2 in the presence of N,N-diisoprophyl-ethylamine.
- A more preferred embodiment of the present invention is a compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; wherein the cholesterol group is cholesterol; wherein the head group is a polyamine group; and wherein the cholesterol group is linked to the head group via a carbamoyl linkage; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH2Cl2 in the presence of N,N-diisoprophylethylamine.
- A highly preferred embodiment of the present invention is a compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; wherein the cholesterol group is cholesterol; wherein the head group is a polyamine group; wherein the cholesterol group is linked to the head group via a carbamoyl linkage; and wherein the polyamine group is a naturally occurring polyamine, such as any one of spermidine, spermine or caldopentamine; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH2Cl2 in the presence of N,N-diisoprophylethylamine.
- The present invention will now be described only by way of examples, in which reference is made to the following Figures:
-
FIG. 1 which is a structure; -
FIG. 2 which is a structure; -
FIG. 3 which is a structure; -
FIG. 4 which is a series of structures; -
FIG. 5 which is a structure; -
FIG. 6 which is a structure; -
FIG. 7 which includes a reaction scheme; -
FIG. 8 which includes a reaction scheme and a Table of results; -
FIG. 9 which includes a reaction scheme and a Table of results; -
FIG. 10 which includes a reaction scheme and a Table of results; -
FIG. 11 which includes a reaction scheme; -
FIG. 12 which includes a reaction scheme and a Table of results; -
FIG. 13 which includes a reaction scheme and a Table of results; -
FIG. 14 which includes a reaction scheme and a Table of results; -
FIG. 15 which includes a reaction scheme and a Table of results; -
FIG. 16 which includes a reaction scheme and a Table of results; -
FIG. 17 which includes a reaction scheme; -
FIG. 18 which includes a reaction scheme and a series of results; -
FIG. 19 which includes a reaction scheme and a series of results; -
FIG. 20 which includes a reaction scheme and a Table of results; -
FIG. 21 which includes a reaction scheme and a Table of results; -
FIG. 22 which presents a model; -
FIG. 23 which presents data from some studies; -
FIG. 24 which presents data from some studies; -
FIG. 25 which presents data from some studies; -
FIG. 26 which presents a reaction scheme; -
FIG. 27 which presents a reaction scheme; -
FIG. 28 which presents a reaction scheme; and -
FIG. 29 which presents some formulae. - In these studies DC-Chol was used as a template for the synthesis of more efficient gene transfer lipids, due to its good gene transfer ability12 and low cytotoxicity13. In particular, the head group of DC-Chol was changed to a series of polyamine head-groups.
- Initial Studies
- Initially, a range of cationic lipids as shown in
FIG. 6 (where m-=1-3, n=1-2; referenced as 2), with head groups based on the naturally occurring polyamine, spermidine (m=3, n=3; referenced as 3) were synthesised. - To prepare these compounds we used aza-Wittig methodology16, and so we made and used a range of suitably protected homologous azides and aldehydes (see
Scheme 1 inFIG. 7 ). - Our initial studies suggested that benzyloxycarbonyl protected aminoazides (see
FIG. 8 , referenced as 4) would be suitable. These could be prepared in three steps and in excellent yield from aminoalcohols (seeFIG. 8 , referenced as 3), by sequential N-benzyloxycarbonylation, mesylation and azidation. - This process and the yields therefrom are shown in
FIG. 8 (seeScheme 2 and Table 1). - The desired aldehyde could also be synthesised from aminoalcohols (see
FIG. 9 , referenced as 5) in excellent yield, this time by N-protection with cholesteryl chloroformate to give alcohols (seeFIG. 9 , referenced as 8), followed by Swern-type oxidation17 to aldehydes (seeFIG. 9 , referenced as 9). - This process and the yields therefrom are shown in
FIG. 9 (seeScheme 3, Table 2). - The aldehydes (9) were isolated as white crystalline solids which, in contrast with analogous aldehydes with different protecting groups, proved to be extremely stable, easy to handle and could be stored for long periods of time without any discernible decomposition.
- The aza-Wittig reaction between azides (4) and aldehydes (9) occurred smoothly in THF to yield, after in situ reduction, protected polyamines (10) in excellent yield. We found that the use of trimethylphosphine rather than triphenylphosphine, led both to higher yields and lower reaction times. The use of molecular sieves also proved advantageous in obtaining consistently good yields, by eliminating adventitious water from the reaction system. Finally, removal of the benzyloxycarbonyl protecting group by hydrogenolysis yielded the desired lipids (2) in quantitative yield. These processes and the yields are shown in
FIG. 10 (see Scheme 4, Table 3). - Liposomes containing the new lipids could be prepared using the following general procedure which by way of example refers to lipid (2) and DOPE.
- Lipid (2) (6 μmol) and DOPE (298 μl of a 10 mg/ml solution in CHCl3, 4 μmol) were added via syringe to freshly distilled CH2Cl2 (5 ml) under a nitrogen atmosphere. 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (5 ml of a 20 mM solution adjusted to pH 7.8) was added. The two phase mixture was sonicated for 3 minutes and the organic solvents were removed under reduced pressure. The resulting liposome suspension was then sonicated for a further 30 min, yielding liposomes with an average diameter of 150 nm (as determined using a Coulter N4 MD photon correlation spectrometer).
- The new compounds yielded the correct analytical data by 1H NMR, 13C NMR, 1R, MS and elemental analyses or HRMS.
- This process therefore yields spermidine containing DC-Chol analogues from readily available starting materials, using aza-Wittig methodology. For these studies reference can also be made to
FIGS. 11-21 . - Further Studies
- The further studies involved the inclusion of higher homologue polyamines such as spermine and unusual polyamines such as caldopentamine into a lipid framework. It is believed that these lipids, when used within the confines of a liposome, provide a DNA-condensing property that results in stronger, more stable liposome/DNA conjugates. Thus, we believe that these properties will improve the overall transfection of, for example, plasmid DNA into, for example, cell lines.
- For these further studies reference can also be made to
FIGS. 11-21 . - Preparation of Methanesulfonate Esters
- To a solution of dry alcohol (1.48 mmol) in dry CH2Cl2 (15 ml) was added triethylamine (0.62 ml, 4.4 mmol) and the solution stirred under nitrogen and cooled to around 0° C. At this point, methanesulfonyl chloride (0.29 ml, 3.7 mmol) in dry CH2Cl2 (5 ml) was added carefully and dropwise to the solution of alcohol. After the addition stirring was continued at 0° C. for 10 minutes and then at RT for 10 minutes. Ice was then added carefully and the reaction quenched for 35 minutes. The CH2Cl2 was diluted five-fold and then extracted with sat. ammonium chloride (70 ml), water (50 ml) and brine (70 ml). The organic layer was then dried over anhydrous sodium sulfate and the solvent removed in vacuo to give a quantitative yield of the crude mesylate.
- Preparation of Azides
- To a stirred mixture of methanesulfonate ester (1.48 mmol), sodium azide (0.48 g, 7.4 mmol, 5 eq.) and sodium iodide (0.222 g, 1.48 mmol) under N2, was added by syringe dry DMF (10 ml) and the suspension heated to 80° C. This was maintained for two hours, and then allowed to cool to room temperature. The slurry was then filtered over Celite™ and the DMF removed under high vacuum to give a pale yellow oil.
- The pale yellow oil was then redissolved in diethylether (100 ml) and washed with water (3×60 ml) and brine (80 ml). The organic layer was dried over anhydrous Na2SO4 and evaporated in vacuo to give the colourless azide. The azide was then purified further by flash column chromatography (ether/acetone 4-30%) to give the pure azide.
- Preparation of Bromides
- To a mixture of methanesulfonate ester (1 mmol) and sodium bromide (0.515 g, 5 mmol, 5 eq.) was added dry DMF (10 ml) via syringe and the solution heated at 80° C. for two hours, and then allowed to cool to room temperature and the slurry filtered over Celite™, and the DMF removed in vacuo. The bromide was then redissolved in diethylether (50 ml) and washed with water (3×30 ml) and brine (50 ml). The organic extract was dried over anhydrous Na2SO4, and the solvent removed in vacuo to give a colourless oil. The bromide was then purified by flash column chromatography (diethylether 20%/
petrol 80% →diethylether) to give pure bromide. - Mono-N-Alkylation with Bromides
- To a stirred solution of bromide (1 mmol) and 4-amino-1-butanol (0.36 g, 4 mmol, 4 eq.) in anhydrous DMF (10 ml) under N2, was added anhydrous K2CO3 (0.276 g, 2 mmol, 2 eq.) and sodium iodide (15 mg, 0.1 mmol, 0.1 eq.). The reaction was stirred for 72 hours at room temperature, until reaction complete. The DMF was evaporated in vacuo and dried exhaustively under high vacuum. The resulting oily solid was redissolved in CH2Cl2 (100 ml) and washed with water (4×50 ml).
- The combined aqueous extracts were then washed with CH2Cl2 (40 ml) and the CH2Cl2 extracts dried over anhydrous Na2SO4. The CH2Cl2 was evaporated in vacuo to give a pale yellow oil.
- Aza-Wittig Reaction
- To a suspension of flame-dried 4 Å molecular sieves (500 mg) and toluene-dried azide (1.08 mmol) in anhydrous THF (9 ml) under a nitrogen atmosphere, was added dropwise a solution of trimethylphosphine (1.2 ml of a 1.0 M solution in THF, 1.19 mmol, 1.1 eq.) via syringe.
- After stirring at room temperature for one hour, the aldehyde (1.19 mmol, 1.1 eq.) in THF (2 ml) was added dropwise via cannula and the reaction mixture stirred for 18 hours. At this point, the THF was evaporated under nitrogen, and the resulting slurry resuspended in dry ethanol (7 ml). To this solution was added sodium borohydride (4.32 ml of 0.5 M solution in diglyme, 2.16 mmol, 2 eq.) via syringe and the reaction stirred for a further 24 hours at room temperature.
- After this, the suspension was filtered over a short pad of Celite™, and the diglyme removed in vacuo. Exhaustive drying prior to work up was carried out, and the resulting oil redissolved in CH2Cl2 (120 ml) and treated with sat. sodium bicarbonate (100 ml), water (120 ml) and brine (120 ml). The organic fraction was dried over anhydrous Na2SO4 and the solvent removed in vacuo to give a pale yellow oil and the crude product purified by flash column chromatography.
- Hydrogenolysis
- To a solution of Z-protected lipid (0.52 mmol, 1 eq.) in ethanol (6 ml) was added cyclohexene (2.11 ml, 20.8 mmol, 40 eq.) followed by palladium on activated carbon (10%, 277 mg, 0.5 eq.) under nitrogen blanket. The solution was then refluxed under nitrogen and the reaction followed by TLC (CH2Cl2/MeOH/NH3 92:7:1).
- After two hours, the catalyst was carefully filtered off under nitrogen, washed with fresh ethanol and the solvent evaporated in vacuo to give a white solid.
- Preparation of Silanols
- To a cooled, stirred solution of alcohol (0.93 mmol), triethylamine (0.39 ml, 2.8 mmol) and DMAP (11.4 mg, 0.093 mmol, 0.1 eq.) in dry CH2Cl2 (1.5 ml) was added dropwise a solution of tert-butylchlorodiphenylsilane (0.6 ml, 2.33 mmol, 2.5 eq.) in dry CH2Cl2 (1.5 ml). The solution was stirred at room temperature for three to five hours at which point CH2Cl2 (45 ml) was added to the reaction mixture and then extracted with sat. sodium bicarbonate (70 ml) and brine (70 ml).
- The CH2Cl2 extracts were dried over anhydrous Na2SO4 and the solvent removed in vacuo to give a pale yellow oil. This was purified by flash column chromatography.
- N-Protection of Aminosilanols
- To an ice-cooled aminosilanol (0.85 mmol) and triethylamine (0.24 ml, 1.7 mmol, 2 eq.) in CH2Cl2 (4 ml) was added dropwise a solution of phenylmethoxycarbonyl chloride (0.26 ml, 1.7 mmol, 2 eq.) in CH2Cl2 (1 ml). The resulting solution was stirred at room temperature for 18 hours. The solution was then diluted with CH2Cl2 (30 ml), washed with saturated ammonium chloride (40 ml) and brine (40 ml). The CH2Cl2 extract was then dried over anhydrous sodium sulfate and evaporated to dryness in vacuo to give a pale yellow oil. The compound was purified by flash column chromatography.
- Preparation of Aldehydes
- To a stirred solution of ethanedioyl dichloride (0.80 ml, 9.3 mmol, 1.5 eq.) in CH2Cl2 (20 ml) at −78° C. under a nitrogen atmosphere was added a solution of DMSO (1.35 ml, 18.6 mmol, 3 eq.) in CH2Cl2 (20 ml) via cannula over a time period of 15 minutes. The resulting solution was stirred for a further 20 minutes after which time a solution of alcohol (6.2 mmol, 1 eq.) in CH2Cl2 (60 ml) was added dropwise via cannula. After a further 30 minutes N,N,N-diisopropylethylamine (3.25 ml, 18.6 mmol, 3 eq.) was added dropwise and the solution warmed slowly to room temperature.
- The pale yellow solution was then washed with saturated ammonium chloride (150 ml), saturated sodium bicarbonate (80 ml) and water (100 ml). The aqueous extracts were combined and washed with CH2Cl2 (100 ml). The CH2Cl2 extracts were combined, washed with brine (100 ml) and dried over anhydrous sodium sulfate. The solvent was then evaporated in vacuo to give a pale yellow solid. The crude aldehyde was then purified by flash column chromatography (ether) to a white solid.
- Deprotection of Silanols
- To a solution of silanol (1 mmol) in THF (5 mmol) was added carefully tetrabutyl ammonium fluoride (TBAF) (1.1 mmol) and the solution stirred for two to three hours. The solution was then diluted with CH2Cl2 (50 ml) and sat. sodium bicarbonate (50 ml) added. The organic phase was collected, washed with water (50 ml) and brine (60 ml). The organic layer was then dried over anhydrous sodium sulfate, and the solvent removed in vacuo. The pale yellow oil was then purified by flash column chromatography.
- Additional Studies
- For these particular studies reference is made inter alia to
FIGS. 22-28 . - In particular,
FIG. 22 is the putative alignment of DC-Chol 1 andDOPE 2 in cationic liposome bilayer. -
FIG. 23 is an example of in vitro optimisation of pCF1-βGal plasmid transfection of CFT1 cells in vitro using complexes of pCF1-βGal and cationic liposomes formulated from DC-Chol analogue 8f′ and DOPE 2 (1:1) molar ratio. CFT1 cells were transfected with an array of different cationic liposome and plasmid ratios in a 96-well plate. The extent of transfection in each well was determined after 2 days by measuring the levels of β-galactosidase expression. Plasmid DNA concentration is expressed as the concentration of nucleotides assuming an average nucleotide FWt of 330. Cationic liposome concentration is expressed in ter-Ms of the concentration of the constituent DC-Chol analogue 8f′ alone. -
FIG. 24 presents ran order of DC-Chol polyamine analogues transfecting CFT1 cells in vitro with the pCF1-βGal plasmid. Gene delivery activity is expressed as a proportion of the activity measured with standard liposomes containing DC-Chol 1 andDOPE 2. The data shown are the averages of four separate experiments, each performed in triplicate. - The ratios in curved brackets refer to the DC-Chol analogue:
DOPE 2 molar ratio used to formulate the liposomes. The numbers in square brackets refer to compound serial numbers. Where appropriate DC-Chol analogue name abbreviations are also included (see experimental). -
FIG. 25 presents the rank order of DC-Chol polyamine analogues transfecting the lungs of female BALB/c mice with the pCF1—CAT plasmid. Mice were instilled with a solution of the plasmid (4 mM nucleotide concentration) and the optimal quantity and ratio of cationic liposome, in a total volume of 100 μl. Gene delivery activity was determined as a function of chloramphenicol acetyl transferase activity in lung homogenates after 2 days. - Data points were from separate experiments with each optimal formulation tested in 4 BALB/c mice. The ratios in curved brackets refer to the DC-Chol analogue:
DOPE 2 molar ratio. The numbers in square brackets refer to compound serial numbers. Where appropriate DC-Chol analogue name abbreviations are also included (see experimental). - Extra studies have shown that the gene delivery efficiency of DC-Chol/DOPE liposomes is equivalent to the performance of liposomes containing DC-
Chol analogue 8c′.[32] - In order to improve to DC-Chol/DOPE liposomes, a simple model for the association of DC-
Chol 1 andDOPE 2 in the bilayer of a cationic liposome was devised (FIG. 22 ). This was based upon the proposed behaviour of cholesterol in bilayer membranes[26] and a liposome model proposed by Felgner and co-workers.[27] - Carbon atoms C-1 to C-9 of the oleoyl side chains of
DOPE 2 pack against the four fused cholesterol rings of DC-Chol 1 so that the phosphate ester group of DOPE and the protonated tertiary amine functionality of DC-Chol 2 are aligned and neutralise each other. The positive charge of the liposome then derives from the protonated ethanolamine side chain ofDOPE 2. On the basis of the recent transfection experiments in mouse and human[24, 25] it was thought that increased transfection efficiency could best be achieved by constructing either DC-Chol or DOPE polyamine analogues which would be expected to interact with DNA more strongly. Since DOPE is sensitive to oxidation of the oleoyl cis-double bonds, we considered that it would be more appropriate to synthesise polyamine analogues of DC-Chol instead. The model (FIG. 22 ) suggested that the methylene group spacing between carbamoyl and the first amine functional group of a given DC-Chol polyamine analogue should be two or at most three, in order to maintain charge complementation withDOPE 2. The preferred DC-Chol polyamine analogues (i.e. polyamine analogues of 3DF-[N—(N′,N′-dimethylaminoethane) carbamoyl]cholesterol) were designed with this constraint in mind. - The syntheses of triamine analogues of DC-Chol were carried out as follows.
- Initially, two different N-
cholesteryloxycarbonylaminoaldehydes 3′ were prepared by N-protection of aminoalcohols 4′ with cholesteryl chloroformate followed by Swern-type oxidation[28] of protectedalcohols 5′ to give thealdehydes 3′ (see Scheme A inFIG. 26 ). Typically speaking aminoaldehydes can be quite unstable and prone to polymerisation but the steric stabilisation of the N-cholesteryl moiety resulted in crystalline compounds which could be stored for extended periods of time without any discernible decomposition. - N-Benzyloxycarbonyl protected aminoazides 6′ were then prepared in three steps from aminoalcohols 4′ using sequential N-benzyloxycarbonylation, mesylation and azidation (Scheme A). Finally,
azides 6′ were coupled toaminoaldehydes 3′ using aza-Wittig methodology[29, 30] giving protected DC-Chol triamine analogues 7′ which were stored at this stage. In our hands, aza-wittig coupling reactions were found to be more efficient with trimethylphosphine rather than the customary triphenylphosphine, in line with literature precedent.[29] Also, the elimination of adventitious water with activated molecular sieves proved helpful to obtain consistently high yields.[29] Just prior to any gene delivery studies, protecting groups were removed by catalytic transfer hydrogenolysis, to givetriamine analogues 8′ (Scheme A) in 44-77% overall yield. The syntheses of tetramine analogues of DC-Chol were carried out in the following way. Several different N-protecteddiaminoalcohols 9′ were prepared by mono N-alkylation of aminoalcohols 4′ with N-benzyloxycarbonyl protected aminoalkylbromides 10′.Bromides 10′ were themselves prepared in three steps from aminoalcohols by sequential N-benzyloxycarbonylation, mesylation and bromination (see Scheme B inFIG. 27 ). Customarily, mono-N-alkylations of primary amines are considered to be difficult to control. Nevertheless, a combination of steric crowding in the reactants and mild reaction conditions are now being found increasingly to prevent over-N-alkylation occurring.[31] Temporary protection of the alcohol functional groups of 9′ as t-butyldiphenylsilylethers, followed by N-benzyloxycarbonylation and fluoride promoted desilylation gave bonafide di-N-benzyloxycarbonyl protected diaminoalcohols which were then converted into diaminoazides 11′ by mesylation followed by azidation (Scheme B). Finally, protected DC-Chol tetramine analogues 12′ were formed by coupling azides 11′ to cholesteryl-aminoaldehydes 3′ by means of the aza-Wittig procedure once more (Scheme B). As for the preparation of 8′ (Scheme A), protecting groups were removed just prior to transfection studies by catalytic transfer hydrogenolysis giving tetramine analogues 13′ (Scheme B) in 12-38% overall yield. Gratifyingly, we found that the mono-N-alkylation procedure could be used equally well to prepare N-cholesteryloxycarbonyl-diaminoaldehyde 14′ from N-cholesterylalcohol 5′ viabromide 15′ (see Scheme C inFIG. 28 ). As a result, several fully protected DC-Chol pentamine analogues 16′ could be prepared by aza-Wittig coupling ofdiaminoaldehyde 14′ to di-N-benzyloxycarbonyl protected diaminoazides 11′. DC-Chol pentamine analogues 17′ were then prepared by hydrogenolysis of the protecting groups in the usual way (Scheme C). - The ability of cationic liposomes containing the different DC-Chol polyamine analogues to mediate gene delivery was analysed both in vitro and in vivo. Cationic liposomes were formulated by hydrating a dried lipid film, containing DC-Cholanalogue and
DOPE 2 in an appropriate molar ratio of either 1:0, 1:1, 1:2 or 2:1 respectively, and vortex mixing.[32] Cationic liposome/plasmid DNA complexes were then prepared by adding appropriately diluted cationic liposome suspensions into equal volumes of aqueous plasmid DNA solutions at 30° C. and allowing the mixture to equilibrate to ambient temperature over 15 min.[32] In vitro studies were then performed with immortalised cystic fibrosis airway epithelial (CFT1) cells followed by in vivo studies in which cationic liposome/plasmid DNA complexes were instilled intranasally into the lungs of female BALB/c mice.[32] Typically, cationic liposome gene delivery was first optimised in vitro so as to establish the best molar ratio of cationic liposome to plasmid DNA (DNA concentration was expressed as nucleotide concentration) as well as the best absolute quantities of both, as illustrated (FIG. 23 ). This optimised combination was then tested in vivo. The in vitro results are shown (FIG. 24 ). Six DC-Chol analogue containing liposomes proved to confer significant improvements on gene delivery efficiency over and above DC-Chol/DOPE liposomes formulated in a similar way. The analogues were 8a′, 8b′, 8e′, 8f′, 13a′ and 17b′, the first four being triamines, the fifth a tetramine and the sixth a pentamine. With one exception, 8f′, these polyamine analogues contain inter-nitrogen methylene group spacings not normally associated with the natural polyamines spermidine 18′ (see for exampleFIG. 29 ),spermine 19′ (see for exampleFIG. 29 ) andpentamine 20′ (see for exampleFIG. 29 ) upon which these structures are based. In vivo (FIG. 25 ), the best DC-Chol analogues were 13c′, 13f′ and especially 17a′. Both 17a′ and 13c′ also contain unnatural methylene group spacings. - Of the best in vivo analogues, 17a′ works about 100-fold more effectively in mouse lung than DC-
Chol 1 and approx 500-fold relative to plasmid DNA alone (FIG. 25 ). Only one other cytofectin has been reported to function at this level of efficacy in vivo, namely the lipid 67 21′ (seeFIG. 29 ), a “T” shaped tetramine analogue of DC-Chol.[32] None of the other reported cytofectins appear to be close to this level of in vivo efficacy with the possible exception of (B1)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis-(dodecyloxy)-1-propanaminium bromide (GAP-DLRIE) 22′ (seeFIG. 29 ) which has been reported to work about 100 fold better than plasmid DNA alone.[33] Other cytofectins have been reported, but frequently have either not yet been used in vivo or else with rather poor results.[21, 34, 35] - Analogues 8f′ and 13f′ have been reported previously, either without synthetic characterisation details[32] or else as impure mixtures known as SpdC and SpC respectively.[34] In the former case, in vitro and in vivo gene delivery behaviours were found to be comparable with our results reported here.[32] In the latter case, SpC was reported not to work well and to be relatively toxic.[34] Our data with analogue 13f′ do not support these observations.
- Experimental Procedure
- The synthetic procedures used to make the DC-Chol polyamine analogues are documented below.
- Scheme A
- Reagents and conditions: i, CH2Cl2 (0.2M), CholOC(O)Cl (0.45 eqv), 5 h, 98-99%; ii, (a) CH2Cl2 (0.1M) (COCl)2 (1.5 eqv), DMSO (3 eqv), −78° C., 15 min; (b) 5′, 15 min; (c) i-Pr2NEt (3 eqv) to r.t., 93-97%; iii, (a) CH2Cl2 (0.2M), PhCH2OC(O)Cl (0.45 eqv), 10 h; (b) CH2Cl2 (0.2M), Et3N (3 eqv), CH3SO2Cl (2.5 eqv), 0° C. to r.t., 15 min; (c) DMF (0.15 M), NaN3 (5 eqv), NaI, 80° C., 2 h, 68-87%; iv, (a) 6′, THF (0.5M), 4 Å molecular sieves, PMe3 (1.15 eqv), 30 min; (b) 3′ (1.1 eqv), 3h; (c) EtOH (0.5 M), NaBH4 (2 eqv), 20 h, 72-90%; v, EtOH (0.2M), c-C6H10 (20 eqv), 10% Pd(C) (0.5 eqv), reflux, 30 min, 99%.
- Scheme B
- Reagents and conditions: i, (a) CH2Cl2 (0.2M), PhCH2OC(O)Cl (0.45 eqv), 10 h; (b) CH2Cl2 (0.2M), Et3N (3 eqv), CH3SO2Cl (2.5 eqv), 0° C. to r.t., 15 min; (c) DMF (0.15 M), NaBr (5 eqv), 80° C., 2 h, 68-87%; ii, 10′, DMF (0.1M), 4′ (5 eqv), K2CO3 (2 eqv), NaI (0.3 eqv), 24-72 h, 74-88%; iii, (a) CH2Cl2 (0.2M), Et3N (1.5 eqv), TBDPSCl (1.2 eqv), DMAP (0.1 eqv), 09AC to r.t., 2-4 h; (b) CH2Cl2 (0.2M), PhCH2OC(O)Cl (1.5 eqv), Et3N (1.5 eqv), 6-10 h; (c) THF (0.5M), TBAF (1.1 eqv), 4-5 h; (d) CH2Cl2 (0.2M), Et3N (3 eqv), CH3SO2Cl (2.5 eqv), 0° C. to r.t., 15 min; (e) DMF (0.15M), NaN3 (5 eqv), NaI, 80° C., 2 h, 37-70%; iv, (a) 11′, THF (0.5M), 4 Å molecular sieves, PMe3 (1.15 eqv), 30 min; (b) 3′ (1.1 eqv), 3h; (c) EtOH (0.5 M), NaBH4 (2 eqv), 20 h, 64-71%; v, EtOH (0.2M), c-C6H10 (20 eqv), 10% Pd(C) (0.5 eqv), reflux, 30 min, 99%.
- Scheme C
- Reagents and conditions: i, (a) CH2Cl2 (0.2M), Et3N (3 eqv), CH3SO2Cl (2.5 eqv), 0° C. to r.t., 15 min; (b) DMF (0.15 M), NaBr (5 eqv), 80° C., 2h, 68-87%; ii, (a) 15′, DMF (0.1M), 4′ (5 eqv), K2CO3 (2 eqv), NaI (0.3 eqv), 24-72 h; (b) CH2Cl2 (0.2M), Et3N (1.5 eqv), TBDPSCl (1.2 eqv), DMAP (0.1 eqv), 0° C. to r.t., 2-4 h; (c) CH2Cl2 (0.2M), PhCH2OC(O)Cl (1.5 eqv), Et3N (1.5 eqv), 6-10 h; (d) THF (0.5M), TBAF (1.1 eqv), 4-5 h; (e) CH2Cl2 (0.1M) (COCl)2 (1.5 eqv), DMSO (3 eqv), −78° C., 15 min; (f) di N-protected diaminoalcohol, 15 min; (g) i-Pr2NEt (3 eqv) to r.t., 53-66%; iii (a) 11′, THF (0.5M), 4 Å molecular sieves, PMe3 (1.15 eqv), 30 min; (b) 14′ (1.1 eqv), 3h; (c) EtOH (0.5 M), NaBH4 (2 eqv), 20 h, 56-74%; iv, EtOH (0.2M), c-C6H10 (20 eqv), 10% Pd(C) (0.5 eqv), reflux, 30 min, 99%.
- Data
- Representative analytical data presented for the most effective analogues in vitro (triamine 8e′,
tetramine 13a′ andpentamine 17b′) and in vivo (tetramine 13f′ andpentamine 17a′) - vmax (CH2Cl2) 3347, 2937, 2905, 2868, 1698, 1534, 1467, 1379 and 1264 cm−1; δH (300 MHz) 5.76 (1H, br s, NHCO), 5.22 (1H, m, H-6′), 4.33 (1H, m, H-3′), 3.08 (2H, m, H-1), 2.65 (2H, t, J 6.5 Hz, H-7), 2.53 (2H, t, J 6.5 Hz, H-3), 2.41 (2H, m, H-5), 2.24-2.12 (2H, m, H-4′), 1.90-1.69 (5H, m, H-2′, H-7′, H-8′), 1.55-0.93 (28H, m, H-2, H4, H-6, H-1′, H-9′, H-11′, H-12′, H-14′ to H-17′, H-20′, H-22′ to H-25′, NH2), 0.88 (3H, s, H-19′), 0.79 (3H, d, J 6.5 Hz, H-21′), 0.73 (6H, dd, J 6.0 and 0.5 Hz, H-26′ and H-27′), 0.55 (3H, s, H-18′); δC (75 MHz) 56.29 (NHC(O)O), 139.77 (C-5′), 122.24 (C-6′), 73.85 (C-3′), 56.59 (C-14′), 56.09 (C-17′), 49.92 (C-9′), 47.61 (C-1), 47.52 (C-3), 42.20 (C-4′), 40.22 (C-5), 39.66 (C-16′), 39.42 (C-24′), 38.57 (C-7), 36.94 (C-2), 36.44 (C-22′), 36.11 (C-8′), 35.71 (C-20′), 33.04 (C-7′), 31.78 (C-6), 28.14 (C-2′), 27.87 (C-25′), 24.19 (C-12′), 23.78 (C-15′), 22.74 (C-23′), 22.49 (C-26′), 20.96 (C-11′), 19.25 (C-19′), 18.65 (C-21′), 11.77 (C-18′); m/z (FAB) 544 (M+H)+, 369 (Chol)+, 95, 43 (Found: (M+H)+, 544.4885. C34H62N3O2 requires (M+H)+, 544.4842).
- Vmax (CH2Cl2) 3584-3245, 2937, 2868, 1695, 1538, 1469, 1379, 1251, 1133 and 1014 cm1; δH (400 MHz) 5.82 (1H, br s, NHCO), 5.23 (1H, m, H-6′), 4.33 (1H, m, H-3′), 3.54-2.55 (16H, m, H-1 to H-4, H-6 to H-9, H2N), 2.21-2.09 (2H, m, H-4′), 1.97-1.73 (5H, m, H-2′, H-7′, H-8′), 1.55-0.99 (23H, m, H-5, H-1′, H-9′, H-11′, H-12′, H-14′ to H-17′, H-20′, H-22′ to H-25′), 0.88 (3H, s, H-19′), 0.78 (3H, d, J 6.0 Hz, H-21′), 0.74 (6H, d, J 6.5 Hz, H-26′ and H-27′), 0.55 (3H, s, H-18′); δC(100 MHz) 156.38 (NHC(O)O), 139.70 (C-5′), 122.30 (C-6′), 73.99 (C-3′), 56.56 (C-14′), 56.05 (C-17′), 51.91 (C-1), 49.88 (C-9′), 47.95 (C-2), 42.18 (C-4′), 41.12 (C-8), 39.63 (C-16′), 39.40 (C-24′), 38.53 (C-2), 36.90 (C-1′), 36.42 (C-22′), 36.08 (C-8′), 35.69 (C-20′), 31.75 (C-7′), 29.62 (C-5), 28.12 (C-2′), 27.86 (C-25′), 24.17 (C-12′), 23.75 (C-15′), 22.73 (C-23′), 22.48 (C-26′), 20.94 (C-11′), 19.24 (C-19′), 18.62 (C-21′), 11.76 (C-18′); m/z (FAB) 573 (M+H)+, 544, 513, 460, 369 (Chol)+, 215, 95 (Found: (M+H)+, 573.5139. C35H65N4O2 requires (M+H)+, 573.5108).
- vmax (CH2Cl2) 3344. 2936, 2855, 1700, 1536, 1468, 1379, 1265, 1122 and 1028 cm−1; δH (300 MHz) 5.69 (1H, br s, NHCO), 5.22 (1H, d, J 4.0 Hz, H-6′), 4.33 (1H, m, H-3′), 3.20 (2H, m, H-1), 2.63 (2H, t, J 6.5 Hz, H-3), 2.55-2.35 (12H, m, H-5, H-8, H-10, H-12. H-14, H-16), 2.23-2.08 (7H, m, H-4, H-9, H-13, H-4′, NH2), 1.90-1.63 (5H, m, H-2′, H-7′, H-8′), 1.57-0.90 (31H, m, H-2, H-6, H-7, H-11, H-15, H-11′, H-9′, H-111′, H-12′, H-14′ to H-17′, H-20′, H-22′ to H-25′), 0.87 (3H, s, H-19′), 0.78 (3H, d, J 6.5 Hz, H-21′), 0.73 (6H, d, J 6.5 Hz, H-26′ and H-27′), 0.55 (3H, s, H-18′); δC (75 MHz) 156.27 (NHC(O)O), 139.79 (C—S′), 122.24 (C-6′), 73.86 (C-3′), 56.58 (C-14′), 56.06 (C-17′), 49.92 (C-9′), 49.62 (C-1), 49.72 (C-3), 49.62 (C-12), 47.52 (C-14), 42.20 (C-4′), 39.65 (C-16′),39.42 C-24′), 38.56 (C-8), 36.93 (C-1′), 36.45 (C-22′), 36.09 (C-8′), 35.69 (C-20′), 31.78 (C-7′), 28.14 (C-2′), 27.88 (C-25′), 27.74 (C-2), 24.19 (C-12′), 23.74 (C-15′), 22.75 (C-23′), 22.49 (C-26′), 20.95 (C-11′), 19.26 (C-19′), 18.64 (C-21′), 11.77 (C-18′); m/z (FAB) 672 (M+H)+, 570, 539, 369 (Chol)+, 84 (Found: (M+H)+, 672.6205. C41H78N5O2 requires (M+H)+, 672.6156).
- vmax (CH2Cl2) 3349, 2937, 2868, 1697, 1468, 1378 and 1253 cm−1; δH (400 MHz) 5.70 (1H, br s, NHCO), 5.27 (1H, m, H-6′), 4.38 (1H, m, H-3′), 3.2 8-3.14 (6H, m, H-1, H-4, H-9, NH2), 2.71 (2H, t, J 6.5 Hz, H-12), 2.63-2.52 (8H, m, H-3, H-5, H-8, H-10), 2.33-2.17 (2H, m, H4′), 1.93-1.85 (5H, m, H-2′, H-7′, H-8′), 1.77-1.07 (29H, m, H-2, H-6, H-7, H-11, H-1′, H-9′, H-11′, H-12′, H-14′ to H-17′, H-20′, H-22′ to H-25′), 1.03 (3H, s, H-19′), 0.97 (3H, d, J 6.0 Hz, H-21′), 0.77 (6H, dd, J 5.0 and 1.5 Hz, H-26′ and H-27′), 0.59 (3H, s, H-18′); δC (100 MHz) 156.25 (NHC(O)O), 139.77 (C-5′), 122.26 (C-6′), 73.87 (C-3′), 56.57 (C-14′), 56.04 (C-17′), 49.90 (C-1), 49.60 (C-9′), 49.47 (C-3), 47.40 (C-10), 42.19 (C-4′), 39.63 (C-16′), 39.40 (C-24′), 38.55 (C-8), 36.92 (C-5), 36.44 (C-22′), 36.08 (C-8′), 35.69 (C-20′), 31.77 (C-7′), 28.13 (C-2′), 27.87 (C-25′), 27.53 (C-2), 24.18 (C-16), 23.74 (C-12′), 22.73 (C-23′), 22.48 (C-26′), 20.94 (C-11′), 19.25 (C-19′), 18.62 (C-21′), 11.76 (C-18′); m/z (FAB) 615 (M+H)+, 539, 369 (Chol)+, 57 (Found: (M+H)+, 615.5626. C38H71N4O2 requires (M+H)+, 615.5577).
- vmax (CH2Cl2) 3568-3295, 2937, 1690, 1537, 1467, 1380, 1130 and 1019 cm−1; δH (300 MHz) 5.76 (1H, br s, NHCO), 5.22 (1H, m, H-6′), 4.32 (1H, m, H-3′), 3.21 (2H, m, H-15), 2.65 (2H, t, J 5.5 Hz, H-13), 2.56-2.45 (12H, m, H-1, H-2, H-4, H-6, H-8, H-11), 2.18-2.05 (2H, m, H-4′), 1.97-1.67 (10H, m, H-3, H-7, H-12, H-2′, H-7′, H-8′, NH2), 1.59-0.91 (29H, m, H1-5, H-9, H-10, H-14, H-1′, H-9′, H-11′, H-12′, H-14′ to H-17′, H-20′, H-22′ to H-25′), 0.86 (3H, s, H-19′), 0.77 (3H, d, J 6.5 Hz, H-21′), 0.72 (6H, dd, J 6.0 and 1.0 Hz, H-26′ and H-27′), 0.53 (3H, s, H-18′); δC (75 MHz) 156.24 (NHC(O)O), 139.77 (C-5′), 122.21 (C-6′), 73.81 (C-3′), 56.57 (C-14′), 56.05 (C-17′), 49.91 (C-9′), 49.67 (C-15), 48.20 (C-13), 42.19 (C-4′), 39.64 (C-16′), 39.40 (C-24′), 38.56 (C-2), 36.92 (C-1′), 36.43 (C-22′), 36.08 (C-8′), 35.68 (C-20′), 31.77 (C-7′), 28.12 (C-2′), 27.86 (C-25′), 27.69 (C-14), 27.63 (C-5), 24.17 (C-12′), 23.74 (C-15′), 22.73 (C-23′), 22.48 (C-26′), 20.94 (C-11′), 19.25 (C-19′), 18.63 (C-21′), 11.76 (C-18′); m/z (FAB) 658 (M+H)+, 539, 369 (Chol)+, 95, 84 (Found: (M+H)+, 658.6056. C40H76N5O2 requires (M+H)+, 658.5999).
- In Vitro and In Vivo Tests
- For the in vitro and in vivo tests, a dried lipid film containing the given DC-Chol analogue and DOPE 2 (in either a 1:0, 1:1, 1:2 or 2:1 respective molar ratio), was hydrated for 10 min in sterile pyrogen-free water and then liposomes were produced by 2 min vortex mixing. The average diameter was between 200-400 nm.[32] Cationic liposomes containing DC-
Chol 1 andDOPE 2 were formulated in the same way described previously.[24, 36] - Cationic liposome/plasmid DNA complexes were then prepared as follows.
- Both cationic liposome suspensions and DNA (either pCF1-βGal plasmid expressing β-galactosidase or pCF1-CAT expressing chloramphenicol acetyl transferase)[32] solutions were separately pre-incubated for 5 min at 30° C., before being diluted to the appropriate final concentrations and then combined. Usually, cationic liposome suspensions were added to an approx. equal volume of plasmid DNA solutions. Complexes were allowed to equilibrate for a minimum of 15 min at ambient temperature and used within 2 h of preparation. In vitro and in vivo gene delivery assays were then performed as described previously using CFT1 cells and female BALB/c mice respectively.[32]
- Discussion
- In theory, genetic trait analysis will eventually be able to identify all the genetic loci which cause or contribute towards disease. With this information, corrective gene(s) may be identified which if introduced into the appropriate organs and cells of the body in vivo should correct the basic pathophysiological defect of the disease. This is the basic concept of gene therapy. Such a simple approach should be capable of curing the disease in contrast to most conventional pharmaceutical approaches which typically treat symptoms only.
- However, introducing potentially corrective gene(s) is not straightforward. Whilst naked DNA may be administered under certain circumstances, for the most part a delivery vehicle or vector is required to effect efficient gene delivery. Several physical, chemical and virus-based vector systems are known but none are sufficiently efficacious for general use in human gene therapy. In spite of this, some vectors are showing some promise, in particular cationic liposome-based gene transfer systems.[21]
- Cationic liposomes are heterogeneous, lipid vesicles typically formed from either a single cationic amphiphile (sometimes known as a cytofectin) or more commonly from a combination of a cationic amphiphile and a neutral lipid. They mediate gene delivery by interacting electrostatically with negatively charged DNA sequences forming complexes which may enter cells by endocytosis[221] or phagocytosisl[23] and then release DNA for expression in the cell nucleus.[21] We have shown that cationic liposomes, formed from the cationic amphiphile 3β-[N—(N′,N-dimethyl-aminoethane)-carbamoyl]cholesterol (DC-Chol) 1 and the neutral phospholipid dioleoyl L-α-phosphatidylethanolamine (DOPE) 2, were able to transfect the lungs of mice in vivo.[24] Since then, some preparatory human clinical trials have been performed using similar DC-Chol/DOPE cationic liposomes.[25]
- Both sets of experiments represent a proof of principle demonstrating that gene therapy with cationic liposomes is possible. However, both sets of experiments also showed that DC-Chol/DOPE cationic liposomes are unlikely to be efficient enough at gene delivery for general use in human gene therapy. Moreover, it is difficult to make improvements in the absence of any understanding of cationic liposome structure/activity relationships.
- The present invention seeks to improve the earlier studies. In addition, the present invention seeks to understand some of the underlying chemical principles behind liposome-mediated gene delivery.
- In this regard, a systematic series of DC-Chol analogues were made which could be incorporated into cationic liposomes and evaluated for gene delivery.
- In conclusion, we have developed a flexible synthetic route to DC-Chol polyamine analogues which has allowed us to identify analogues with optimised methylene group spacing between amine functional groups for both in vitro and in vivo gene delivery On the whole, so far we have found that unnatural spacing appears to work better. Without wishing to be bound by theory, perhaps, such polyamines have a slightly weakened interaction with DNA which facilitates the release of DNA into the cytoplasm, after transfer of the cationic liposome/DNA complex across the outer cell membrane.
- At present, evidence so far suggests that our preferred DC-Chol analogue for in vivo studies and application is N‥-cholesteryloxycarbonyl-3,7,12-triaza-1,15-penta-decane-diamine (CTAP) 17a′. This compound is a novel pentamine of a type not previously shown to transfect cells. The efficacy of this compound appears to meet the necessary levels apparently required for a cytofectin to have realistic potential clinical use.[21, 24.25, 32]
- In summation, in the above examples liposomes were prepared from compounds comprising a cholesterol component and a head group component. The design of the compounds, which were used as cationic lipids, concentrated on the direct manipulation of the head group. With these compounds, the presence of the carbamoyl linkage is believed to be advantageous for low cytotoxicity and the presence of cholesterol is believed to be advantageous for the stabilisation of the liposomal bilayer. In these studies, we were able to alter the identity of the head group in order to increase the net positive charge of the liposome. Increasing the net positive charge is advantageous because it is believed to increase the DNA binding ability and the efficiency of gene transfer of the resultant liposome. Other modifications of the present invention will be apparent to those skilled in the art.
-
- 1. W F Anderson, Science, 1992, 256, 808.
- 2. F D Ledley, Current Opinion in Biotechnology, 1994, 5, 626;
- K F Kozarsky, et al, ibid, 1993, 3, 499;
- Gordon, et al, ibid, 1994, 5, 611.
- 3. C P Hodgon, BioTech, 1995, 13, 222.
- 4. P L Felgner, et al., Proc Natl Acad Sci USA, 1987, 84, 7413;
- Felgner, et al, Nature, 1989, 337, 387;
- H-J Burger, et al, Proc Natl Acad Sci USA, 1992, 89, 2145.
- 5. Malone, et al, Proc Natl Acad Sci USA, 1989, 86, 6077.
- 6. M-Y Chiang, et al., J Biol Chem, 1991, 226, 18162.
- 7. R J Debs, et al, J Biol Chem, 1990, 265, 10189;
- C Walker, et al, Proc Natl Acad Sci USA, 1992, 89, 7915.
- 8. A D Bangham, Hospital Practice, 1992, 27, 51.
- 9. J-P, Behr, et al, Proc Natl Acad Sci USA, 1989, 86, 6982;
- R Leventis, et al, Biochirn Biophys Acta, 1990, 1023, 124.
- 10. X Gao, et al, Gene Therapy, 1995, 2, 710.
- 11. R Stribling, et al, Proc Natl Acad Sci USA, 1992, 89, 11277.
- 12. E W F W Alton, et al, Nature Genetics, 1993, 5, 135.
- 13. X Gao, et al, Biochim Biophys Res Commun, 1991, 179, 280.
- 14. J E Morgan, et al, Arch Biochem Biophys, 1986, 246, 225.
- 15. A E Pegg, Biochem, 1986, 234, 249.
- 16. H Staudinger, et al, Helv Chim Acta, 1919, 2, 635;
- S Knapp, et al, J Org Chem, 1992, 57, 6239
- 17. K Omura, et al, Tetrahedron, 1978, 34, 1651.
- 18. J K Guy-Caffey, et al, 3 Biol Chem, 1995, 270, 31391.
- 21. a) X. Gao, L. Huang, Gene Ther. 1995, 2, 710-722, and references therein;
- b) A. D. Miller, R. G. Cooper, C. J. Etheridge, L. Stewart in Microspheres, Microcapsules and Liposomes (Ed. R. Arshady), John Wiley & Sons, 1997, in press, and references therein; c) P. L. Feigner, Hum. Gene Ther. 1996, 7, 1791-1793.
- 22. a) H. Farhood, N. Serbina, L. Huang, Biochim. Biophys. Acta 1995, 1235, 289-295;
- b) J. Zabner, A. J. Fasbender, T. Moninger, K. A. Poellinger, M. J. Welsh, J. Biol. Chem. 1995, 270, 18997-19007.
- H. Mitsui, L. G. Johnson, S. H. Randell, R. C. Boucher, J. Biol. Chem. 1997, 272, 1117-1126.
- 24. E. W. F. W. Alton, P. G. Middleton, N.J. Caplen, S. N. Smith D. M. Steel, F. M. Munkonge, P. K. Jeffery, D. M. Geddes, S. L. Hart, R. Williamson, K. I. Fasold, A. D. Miller, P. Dickinson, B. J. Stevenson, G. McLachlan, J. R. Dorin, D. J. Poreous,
Nature Genetics 1993, 5, 135-142. - 25. a) N.J. Caplen, E. W. F. W. Alton, P. G. Middleton, J. R. Dorin, B. J. Stevenson, X. Gao, S. R. Durham, P. K. Jeffery, M. E. Hodson, C. Coutelle, L. Huang, D. J. Porteous, R. Williamson, D. M. Geddes,
Nature Medicine 1995, 1, 39-46; - b) G. J. Nabel, E. G. Nabel, Z.-y. Yang, B. A. Fox, G. E. Plautz, X. Gao, L. Huang, S. Shu, D. Gordon, A. E. Chang, Proc. Natl.
Acad. Sci. USA 1993, 90, 11307-11311. - 26. Liposomes: a practical approach (Ed.: R. R. C. New), IRL Press, Oxford, 1990.
- 27. J. H. Felgner, R. Kumar, C. N. Sridhar, C. J. Wheeler, Y. J. Tsai, R. Border, P. Ramsey, M. Martin, P. L. Felgner, J. Biol. Chem. 1994, 269, 2550-2561.
- 28. K. Omura, D. Swern, Tetrahedron 1978, 34, 1651-1660.
- 29. S. Knapp, J. J. Hale, M. Bastos, A. Molina, K. Y. Chen, J. Org. Chem. 1992, 57, 6239-6256
- 30. (a) H. Staudinger, J. Meyer, Helv. Chim.
Acta 1919, 2, 635-646; - (b) E. Fabiano, B. T. Golding, M. M. Sadeghi, Synthesis 1987, 190-192;
- (c) B. T. Golding, M. C. O'Sullivan, L. L. Smith, Tetrahedron Lett. 1988, 29, 6651-6654;
- (d) Y. G. Gololobov, L. F. Kasukhin, Tetrahedron 1992, 48, 1353-1406;
- (e) A. W. Johnson, W. C. Kaska, K. A. O. Starzewski, D. A. Nixon, Ylides and Imines of Phosphorus (Ed.: A. W. Johnson), J. Wiley and Sons, New York, 1993. chap. 13, pp. 403-483.
- 31. (a) J. E. Baldwin, R. M. Adlington, A. S. Elend, M. L. Smith, Tetrahedron 1995, 51, 11581-11594;
- (b) R. M. Moriarty, S. M. Tuladhar, L. Guo, S. Wehrli, Tetrahedron Lett. 1994, 35, 8103-8106.
- 32. E. R. Lee, J. Marshall, C. S. Siegel., C. Jiang, N. S. Yew, M. R. Nichols, J. B. Nietupski, R. J. Ziegler, M. B. Lane, K. X. Wang, N. C. Wan, R. K. Scheule, D. J. Harris, A. E. Smith, S. H. Cheng, Hum. Gene Ther. 1996, 7, 1701-1717.
- 33. C. J. Wheeler, P. L. Felgner, Y. J. Tsai, J. Marshall, L. Sukhu, S. G. Doh, J. Hartikka, J. Nietupski, M. Manthorpe, M. Nichols, M. Plewe, X. Liang, J. Norman, A. Smith, S. H. Cheng, Proc. Natl.
Acad. Sci. USA 1996, 93, 11454-11459. - 34. J. K. Guy-Caffey, V. Bodepudi, J. S. Bishop, K. Jayaraman, N. Chaudhary, J. Biol. Chem. 1995, 270, 31391-31396.
- 35. a) J.-P. Vigneron, N. Oudrhiri, M. Fauquet, L. Vergely, J.-C. Bradley, M. Basseville, P. Lehn, J.-M. Lehn, Proc. Natl.
Acad. Sci. USA 1996, 93, 9682-9686; - b) J. G. Lewis, K.-Y. Lin, A. Kothavale, W. M. Flanagan, M. D. Matteucci, B. De Prince, R. A. Mook Jr., R. W. Hendren, R. W. Wagner, ibid 1996, 93, 3176-3181;
- c) D. Moradpour, J. I. Schauer, V. R. Zurawski Jr., J. R. Wands, R. H. Boutin, Biochem. Biophys. Res. Commun. 1996, 221, 82-88.
- 36. X. Gao. L. Huang, Biochem. Biophys. Res. Commun. 1991, 179, 280-285.
Claims (50)
1. A compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; and wherein the head troup is more positive than the head group of DC-Chol; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH2Cl2 in the presence of N,N-diisoprophylethylamine.
2-22. (canceled)
23. A method for treating a genetic disorder, or condition or disease in a patient in need of treatment, comprising:
administering an effective amount of a compound comprising a cholesterol group or derivative thereof having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; further wherein the head group is a straight chain polyamine; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group.
24. The method according to claim 23 wherein the cholesterol group or derivative thereof is cholesterol.
25. The method according to claim 23 wherein the cholesterol group is linked to the head group via a carbamoyl linkage.
32. The method according to claim 23 , wherein the compound is a cationic lipid compound.
33. The method according to claim 32 , wherein the cationic lipid compound is in admixture with or associated with a nucleotide sequence.
34. The method according to claim 23 , wherein the compound is a cationic liposome formed from a cationic lipid compound.
35. The method according to claim 34 , wherein the cationic liposome is in admixture with or associated with a nucleotide sequence.
36. A method for treating a genetic disorder, or condition or disease in a patient in need of treatment, comprising:
administering an effective amount of a compound selected from the group consisting of cationic lipid compounds, cationic liposomes formed from cationic lipid compounds, cationic lipid compounds in admixture with or associated with a nucleotide sequence, cationic liposomes, formed from a cationic lipid compound, in admixture with or associated with a nucleotide sequence, and combinations thereof,
the compound comprising a cholesterol group or derivative thereof having linked thereto a head group; wherein the head group is more positive than the head group of DC-Choi; further wherein the head group is a straight chain polyamine; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group.
37. The method according to claim 36 wherein the cholesterol group or derivative thereof is cholesterol.
38. The method according to claim 36 wherein the cholesterol group is linked to the head group via a carbamoyl linkage.
45. A method for treating a genetic disorder, or condition or disease in a patient in need of treatment, comprising:
administering an effective amount of a composition, the composition comprising:
i. a compound selected from the group consisting of cationic lipid compounds, cationic liposomes formed from a cationic lipid compound, and combinations thereof, the compound comprising a cholesterol group or derivative thereof having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; further wherein the head group is a straight chain polyamine; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group, and
ii. a pharmaceutical, and optionally a pharmaceutically acceptable diluent, carrier or excipient.
46. The method according to claim 45 wherein the cholesterol group or derivative thereof is cholesterol.
47. The method according to claim 45 wherein the cholesterol group is linked to the head group via a carbamoyl linkage.
54. A method for treating a genetic disorder or condition or disease in a patient in need of treatment, comprising:
administering an effective amount of a composition comprising a compound selected from the group consisting of cationic lipid compounds, cationic lipid compounds in admixture with or associated with a nucleotide sequence, cationic liposomes (formed from a cationic lipid compound) in admixture with or associated with a nucleotide sequence, and combinations thereof;
the compound comprising a cholesterol group or derivative thereof having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; further wherein the head group is a straight chain polyamine; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group.
55. The method according to claim 54 wherein the cholesterol group or derivative thereof is cholesterol.
56. The method according to claim 54 wherein the cholesterol group is linked to the head group via a carbamoyl linkage.
63. The method according to claim 54 wherein the composition further comprises a pharmaceutical.
64. The method according to claim 63 , wherein the composition further comprises a pharmaceutically acceptable diluent, carrier or excipient.
65. A method for the treatment of a genetic disorder or condition or disease in a patient in need thereof, comprising administering a cationic lipid compound, the compound comprising a cholesterol group or derivative thereof having linked thereto a head group, wherein the head group is more positive than the head group of DC-Chol; further wherein the head group is a polyamine group which is a straight chain polyamine group; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group.
66. A method for the treatment of a genetic disorder or condition or disease in a patient in need thereof, comprising administering a cationic liposome formed from a cationic lipid compound, the compound comprising a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; further wherein the head group is a polyamine group which is a straight chain polyamine group; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group.
67. A method for the treatment of a genetic disorder or condition or disease in a patient in need thereof, comprising administering a cationic lipid compound in admixture with or associated with a nucleotide sequence, the compound comprising a cholesterol group or derivative thereof having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; further wherein the head group is a polyamine group which is a straight chain polyamine group; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group.
68. A method for the treatment of a genetic disorder or condition or disease in a patient in need thereof, comprising administering a cationic liposome in admixture with or associated with a nucleotide sequence, wherein the cationic liposome is formed from a cationic lipid compound, the compound comprising a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; further wherein the head group is a polyamine group which is a straight chain polyamine group; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group.
69. A method for the treatment of a genetic disorder or condition or disease in a patient in need thereof, comprising administering a pharmaceutical composition comprising
(i) a cationic lipid compound, the compound comprising a cholesterol group or derivative thereof having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; further wherein the head group is a polyamine group which is a straight chain polyamine group; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group; and
(ii) a pharmaceutical and, optionally, a pharmaceutically acceptable diluent, carrier or excipient.
70. A method for treatment of a genetic disorder or condition or disease in a patient in need thereof, comprising administering a pharmaceutical composition comprising:
(i) a cationic liposome formed from a cationic lipid compound, the compound comprising a cholesterol group having linked thereto a head group; wherein the head group is more positive than the head group of DC-Chol; further wherein the head group is a polyamine group which is a straight chain polyamine group; further wherein two or more of the amine groups of the polyamine group are separated by an ethylene group; and
(ii) a pharmaceutical and, optionally, a pharmaceutically acceptable diluent, carrier or excipient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/868,184 US20080075763A1 (en) | 1996-05-24 | 2007-10-05 | Polycationic sterol derivatives as transfection agents |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9610944.2A GB9610944D0 (en) | 1996-05-24 | 1996-05-24 | A compound |
GB9610944.2 | 1996-05-24 | ||
GB9705498.5 | 1997-03-17 | ||
GBGB9705498.5A GB9705498D0 (en) | 1996-05-24 | 1997-03-17 | A compound |
PCT/GB1997/001426 WO1997045442A1 (en) | 1996-05-24 | 1997-05-23 | Polycationic sterol derivatives as transfection agents |
US09/194,267 US6756054B1 (en) | 1996-05-24 | 1997-05-23 | Polycationic sterol derivatives as transfection agents |
US10/770,294 US20040156890A1 (en) | 1996-05-24 | 2004-02-02 | Polycationic sterol derivatives as transfection agents |
US11/868,184 US20080075763A1 (en) | 1996-05-24 | 2007-10-05 | Polycationic sterol derivatives as transfection agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/770,294 Continuation US20040156890A1 (en) | 1996-05-24 | 2004-02-02 | Polycationic sterol derivatives as transfection agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080075763A1 true US20080075763A1 (en) | 2008-03-27 |
Family
ID=26309393
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/194,267 Expired - Fee Related US6756054B1 (en) | 1996-05-24 | 1997-05-23 | Polycationic sterol derivatives as transfection agents |
US10/770,294 Abandoned US20040156890A1 (en) | 1996-05-24 | 2004-02-02 | Polycationic sterol derivatives as transfection agents |
US11/868,184 Abandoned US20080075763A1 (en) | 1996-05-24 | 2007-10-05 | Polycationic sterol derivatives as transfection agents |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/194,267 Expired - Fee Related US6756054B1 (en) | 1996-05-24 | 1997-05-23 | Polycationic sterol derivatives as transfection agents |
US10/770,294 Abandoned US20040156890A1 (en) | 1996-05-24 | 2004-02-02 | Polycationic sterol derivatives as transfection agents |
Country Status (6)
Country | Link |
---|---|
US (3) | US6756054B1 (en) |
EP (1) | EP0918790B1 (en) |
JP (1) | JP4340330B2 (en) |
AU (1) | AU2911197A (en) |
DE (1) | DE69727384T2 (en) |
WO (1) | WO1997045442A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014033453A1 (en) * | 2012-08-28 | 2014-03-06 | Medical Research Council | Nanoparticle formulation |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939401A (en) * | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
US6331524B1 (en) | 1994-12-09 | 2001-12-18 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy |
US5948767A (en) * | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
US6383814B1 (en) | 1994-12-09 | 2002-05-07 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US6197332B1 (en) | 1997-08-13 | 2001-03-06 | Chiron Corporation | Lipid-conjugated polyamide compounds and related compositions and methods thereof |
SE513149C2 (en) * | 1997-12-05 | 2000-07-17 | Katarina Edwards | Drug distribution system with two-step targeting, to specific cells or tissue and to its cell nucleus |
GB9808268D0 (en) * | 1998-04-17 | 1998-06-17 | Imp College Innovations Ltd | Compound |
KR20010069179A (en) * | 1999-05-28 | 2001-07-23 | 박종상 | Cationic lipids for gene transfer and Preparation Method thereof |
FR2797188A1 (en) * | 1999-08-04 | 2001-02-09 | Univ Paris Nord Laboratoire De | CATIONIC LIPID COMPOUNDS AND THEIR USE FOR THE TRANSFER OF NEGATIVELY CHARGED SUBSTANCES OF THERAPEUTIC INTEREST |
AU1556701A (en) * | 1999-12-02 | 2001-06-12 | Tomohiko Ohwada | Reagents for gene transfer |
EP1351972B1 (en) * | 2000-12-12 | 2006-03-01 | Mitsubishi Chemical Corporation | Lipids comprising an aminoxy group |
EP1669366A1 (en) * | 2000-12-12 | 2006-06-14 | Mitsubishi Chemical Corporation | Lipids comprising an aminoxy group |
DE10109898A1 (en) | 2001-02-21 | 2002-09-05 | Novosom Gmbh | Variable charge lipids |
US7906122B2 (en) | 2003-06-18 | 2011-03-15 | Yissum Research Development Company Of The Hebrew University Of Jersusalem | Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination |
EP1638610B1 (en) * | 2003-06-18 | 2015-03-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingoid polyalkylamine conjugates for vaccination |
GB0418172D0 (en) * | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
JP2008509205A (en) * | 2004-08-13 | 2008-03-27 | アイシー・ベック・リミテッド | Vector containing polymer-modified siRNA liposomes |
GB0425556D0 (en) * | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Novel compounds |
US20060211004A1 (en) | 2005-02-15 | 2006-09-21 | Ilsley Diane D | Methods and compositions for determining non-specific cytotoxicity of a transfection agent |
EP2279726A3 (en) | 2005-05-26 | 2012-06-20 | Biorest Ltd. | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
EP2125031B1 (en) * | 2006-12-19 | 2017-11-01 | Marina Biotech, Inc. | Lipids and lipid assemblies comprising transfection enhancer elements |
CA2710713C (en) | 2007-12-27 | 2017-09-19 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
AU2009236219B8 (en) | 2008-04-15 | 2015-06-25 | Arbutus Biopharma Corporation | Silencing of CSN5 gene expression using interfering RNA |
GB0908963D0 (en) | 2009-05-22 | 2009-07-01 | Imuthes Ltd | Compositions |
US20130164380A1 (en) | 2010-06-17 | 2013-06-27 | Actogenix Nv | Compositions and methods for treating inflammatory conditions |
US10849975B2 (en) | 2011-02-03 | 2020-12-01 | Thomas Jefferson University | Multivalent vaccines for rabies virus and filoviruses |
WO2013075132A1 (en) | 2011-11-17 | 2013-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Therapeutic rna switches compositions and methods of use |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
CZ303963B6 (en) * | 2012-01-13 | 2013-07-17 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Spermin-type lipopolyamines for construction of liposomal transfection systems |
US20160015808A1 (en) | 2012-02-21 | 2016-01-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Tam receptors as virus entry cofactors |
MX2014010016A (en) | 2012-02-21 | 2015-06-05 | Inst Nat Sante Rech Med | Tim receptors as virus entry cofactors. |
JP2015524418A (en) | 2012-07-27 | 2015-08-24 | アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | CD147 as a receptor for pili-mediated adhesion of Neisseria meningitidis to vascular endothelial cells |
BR112015006176B1 (en) | 2012-09-21 | 2023-04-18 | Intensity Therapeutics, Inc | USE OF A THERAPEUTIC AGENT AND AN INTRACELLULAR PERMEATION ENHANCEMENT AGENT |
SG11201702662UA (en) | 2014-10-02 | 2017-04-27 | Protiva Biotherapeutics Inc | Compositions and methods for silencing hepatitis b virus gene expression |
GB2545368B (en) | 2014-10-20 | 2021-04-21 | Elysium Therapeutics Inc | Diversion-resistant opioid formulations |
WO2016164827A1 (en) | 2015-04-09 | 2016-10-13 | Bikanta Corporation | Imaging systems and methods using fluorescent nanodiamonds |
WO2016197132A1 (en) | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
WO2017019891A2 (en) | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
CN109069520A (en) | 2016-02-25 | 2018-12-21 | 应用生物实验室公司 | Protect the composition and method of airborne pathogen and stimulant |
US20170360815A1 (en) | 2016-02-25 | 2017-12-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
EP4104854A3 (en) | 2016-04-04 | 2023-03-08 | The United States of America as represented by the Secretary of the Department of Health and Human Services | Multivalent vaccines for rabies virus and coronaviruses |
US20200352913A1 (en) | 2017-11-23 | 2020-11-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating dengue virus infection |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767099A (en) * | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2861262B2 (en) * | 1990-05-23 | 1999-02-24 | 東ソー株式会社 | Amino acid derivative and method for producing the same |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5972600A (en) * | 1992-04-03 | 1999-10-26 | The Regents Of The University Of California | Separation of active complexes |
ES2123133T3 (en) * | 1993-03-10 | 1999-01-01 | Magainin Pharma | STEROIDIAL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE STEROIDIAL DERIVATIVES AND USE OF THESE STEROIDIAL AS ANTIBIOTICS OR DISINFECTANTS. |
US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
AU3512595A (en) * | 1994-09-13 | 1996-03-29 | Magainin Pharmaceuticals, Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
US6071890A (en) * | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
EP0830368A1 (en) * | 1995-06-07 | 1998-03-25 | Genta Incorporated | Novel carbamate-based cationic lipids |
US5811406A (en) * | 1995-06-07 | 1998-09-22 | Regents Of The University Of California | Dry powder formulations of polynucleotide complexes |
CA2223921A1 (en) * | 1995-06-07 | 1996-12-19 | Francis C. Szoka, Jr. | Stabilization of polynucleotide complexes |
-
1997
- 1997-05-23 AU AU29111/97A patent/AU2911197A/en not_active Abandoned
- 1997-05-23 DE DE69727384T patent/DE69727384T2/en not_active Expired - Lifetime
- 1997-05-23 US US09/194,267 patent/US6756054B1/en not_active Expired - Fee Related
- 1997-05-23 EP EP97923255A patent/EP0918790B1/en not_active Expired - Lifetime
- 1997-05-23 WO PCT/GB1997/001426 patent/WO1997045442A1/en active IP Right Grant
- 1997-05-23 JP JP54184097A patent/JP4340330B2/en not_active Expired - Fee Related
-
2004
- 2004-02-02 US US10/770,294 patent/US20040156890A1/en not_active Abandoned
-
2007
- 2007-10-05 US US11/868,184 patent/US20080075763A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5767099A (en) * | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014033453A1 (en) * | 2012-08-28 | 2014-03-06 | Medical Research Council | Nanoparticle formulation |
CN104837482A (en) * | 2012-08-28 | 2015-08-12 | 医学研究委员会 | Nanoparticle formulation |
US20150224054A1 (en) * | 2012-08-28 | 2015-08-13 | Imperial Innovations Ltd | Nanoparticle formulation |
US10201499B2 (en) * | 2012-08-28 | 2019-02-12 | United Kingdom Research And Innovation | Nanoparticle formulation |
Also Published As
Publication number | Publication date |
---|---|
JP4340330B2 (en) | 2009-10-07 |
WO1997045442A1 (en) | 1997-12-04 |
EP0918790A1 (en) | 1999-06-02 |
DE69727384T2 (en) | 2004-11-04 |
JP2000510151A (en) | 2000-08-08 |
US6756054B1 (en) | 2004-06-29 |
EP0918790B1 (en) | 2004-01-28 |
DE69727384D1 (en) | 2004-03-04 |
AU2911197A (en) | 1998-01-05 |
US20040156890A1 (en) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6756054B1 (en) | Polycationic sterol derivatives as transfection agents | |
Cooper et al. | Polyamine Analogues of 3β‐[N‐(N′, N′‐Dimethylaminoethane) carbamoyl] cholesterol (DC‐Chol) as Agents for Gene Delivery | |
US7507859B2 (en) | Functional synthetic molecules and macromolecules for gene delivery | |
US5851548A (en) | Liposomes containing cationic lipids and vitamin D | |
US5925628A (en) | Cationic amphiphiles for intracellular delivery of therapeutic molecules | |
JP2000502061A (en) | Cationic lipid complex | |
US20090221684A1 (en) | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | |
AU731503B2 (en) | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules | |
US5739271A (en) | Thiocationic lipids | |
JPH11511757A (en) | Composition comprising a cationic amphiphile and an auxiliary lipid for intracellular administration of a therapeutic molecule | |
AU3659097A (en) | Cationic amphiphile/ DNA complexes | |
JPH05508626A (en) | Cationic lipids for intracellular delivery of biologically active molecules | |
US5711964A (en) | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D | |
JP2000504579A (en) | Compositions for transfection of higher eukaryotic cells | |
US5948925A (en) | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids | |
US5912239A (en) | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules | |
US6583301B1 (en) | Lipids | |
JP2005515990A (en) | Compound | |
JPH11507031A (en) | Thiocationic lipids, pharmaceutical compositions and methods of using the same | |
US5952516A (en) | Cationic amphiphiles containing multiplesteroid lipophilic groups | |
US5759519A (en) | Method for the intracellular delivery of biomolecules using thiocationic lipids | |
US5756352A (en) | Thiocationic lipid-nucleic acid conjugates | |
EP1187807B1 (en) | Bipolar lipids and their use for the delivery of bioactive substances | |
US20240293318A1 (en) | Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions | |
WO2001042200A1 (en) | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |